Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cardiovascular disease wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac surgery wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Aortic stenosis wikipedia , lookup
Myocardial infarction wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
University of Iowa Iowa Research Online Theses and Dissertations Summer 2012 Cardiovascular end-organ damage in response to increased blood pressure variability : impact of oxidative stress Kevin Richard Rarick University of Iowa Copyright 2012 Kevin Richard Rarick This dissertation is available at Iowa Research Online: http://ir.uiowa.edu/etd/3370 Recommended Citation Rarick, Kevin Richard. "Cardiovascular end-organ damage in response to increased blood pressure variability : impact of oxidative stress." PhD (Doctor of Philosophy) thesis, University of Iowa, 2012. http://ir.uiowa.edu/etd/3370. Follow this and additional works at: http://ir.uiowa.edu/etd Part of the Systems and Integrative Physiology Commons CARDIOVASCULAR END-ORGAN DAMAGE IN RESPONSE TO INCREASED BLOOD PRESSURE VARIABILITY: IMPACT OF OXIDATIVE STRESS by Kevin Richard Rarick An Abstract Of a thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree in Integrative Physiology in the Graduate College of The University of Iowa July 2012 Thesis Supervisor: Associate Professor Harald M. Stauss 1 ABSTRACT Baroreflex sensitivity (BRS) is often reduced in elderly populations and patients with chronic cardiovascular diseases leading to a concomitant rise in blood pressure variability (BPV) that is associated with increased cardiovascular related morbidity and mortality. Thus, there is a need to better understand the mechanisms by which BPV causes cardiovascular end-organ damage. Animal studies using sinoaortic denervation (SAD) to increase BPV have demonstrated pathologic changes in the structure of the heart and blood vessels; however, there is a paucity of data investigating changes in functional measures of the heart and smaller, resistance type arteries. Furthermore, the pathogenic mechanisms involved in BPV-induced cardiovascular end-organ damage remain unknown. Baroreceptor denervation results in multiple cardiac stressors, many of which are associated with production of reactive oxygen species. Oxidative stress is known to promote cardiovascular end-organ damage but it is unclear if it plays a role in models of increased BPV. Thus, this study was designed to investigate the functional responses of smaller resistance type arteries and the heart to chronic exposure to enhanced BPV. In addition, the role of oxidative stress on these functional responses in a normotensive rat model of increased BPV was also investigated. Rats were subjected to either SAD surgery or a sham procedure and were observed for six weeks. To determine the role of oxidative stress, SAD rats were either treated with the superoxide dismutase mimetic tempol or left untreated. During the observation period, mean blood pressure remained normotensive, whereas baroreflex sensitivity was reduced and BPV increased two to three fold. Weekly in vivo assessment of vascular function of the long posterior ciliary artery (LPCA) demonstrated a significant reduction in endothelial-dependent dilation starting three weeks after SAD surgery compared to the sham group. Endothelial- 2 independent dilation was not affected by SAD. Structural changes were not evident in the LPCA following SAD. However, structural (wall thickness, wall area, and wall area/lumen area ratio) and functional (strain and distensibility) changes were observed in the aorta. Cardiac structural (hypertrophy) and functional (diastolic dysfunction) effects were also evident following six weeks of increased BPV. Antioxidant treatment with tempol did not have any effect on the SAD-induced increase in BPV or decrease in BRS. Nevertheless, chronic tempol treatment prevented or reduced the cardiovascular endorgan damage (endothelial-dependent vascular dysfunction, decreased aortic distensibility, cardiac and vascular hypertrophy, and cardiac dysfunction) observed in the untreated SAD group. These findings suggest that the pathology observed following SAD is at least partly mediated by oxidative stress. Antioxidant treatment in patients with increased BPV (e.g., hypertension, diabetes, heart failure) may prevent or ameliorate cardiovascular end-organ damage and reduce the overall risk for cardiovascular disease events. Abstract Approved: ______________________________________________________ Thesis Supervisor ______________________________________________________ Title and Department _______________________________________________________ Date CARDIOVASCULAR END-ORGAN DAMAGE IN RESPONSE TO INCREASED BLOOD PRESSURE VARIABILITY: IMPACT OF OXIDATIVE STRESS by Kevin Richard Rarick A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree in Integrative Physiology in the Graduate College of The University of Iowa July 2012 Thesis Supervisor: Associate Professor Harald M. Stauss Graduate College The University of Iowa Iowa City, Iowa CERTIFICATE OF APPROVAL _________________________ PH.D. THESIS ____________ This is to certify that the Ph. D. thesis of Kevin Richard Rarick has been approved by the Examining Committee for the thesis requirement for the Doctor of Philosophy degree in Integrative Physiology at the July 2012 graduation. Thesis Committee: _______________________________ Harald M. Stauss, Thesis Supervisor _______________________________ Kevin C. Kregel _______________________________ Warren G. Darling _______________________________ Gary L. Pierce _______________________________ Mark W. Chapleau TABLE OF CONTENTS LIST OF FIGURES .......................................................................................................... .iv LIST OF ABBREVIATIONS ............................................................................................ vi CHAPTER I. INTRODUCTION ...............................................................................................1 Background ..................................................................................................1 Review of Literature ....................................................................................2 Clinical importance of BPV .............................................................2 Sinoaortic denervation as a normotensive model of BPV ...............3 SAD-induced cardiovascular end-organ damage.............................5 Cardiac changes following SAD ..........................................5 Vascular changes following SAD ........................................5 Mechanisms of SAD induced cardiovascular-end organ damage ...7 Renin angiotensin system ....................................................7 Mitogen activated protein kinases .......................................9 Oxidative stress ..................................................................10 Tempol as a potential treatment option ..........................................11 Effects of tempol on the heart ............................................11 Effects of tempol on the vessels.........................................13 Purpose of Study .......................................................................................14 II. METHODS.......................................................................................................16 Experimental Design ..................................................................................16 Animals ..........................................................................................16 Experimental protocol ...................................................................16 Surgical procedures .......................................................................17 Weekly Measures ......................................................................................18 Telemetric blood pressure recording ............................................18 Weekly in vivo vascular analysis of the LPCA ............................18 Determination of drug doses for LPCA functional analysis .........19 Endothelial dependent/independent dilation of the LPCA ...........20 LPCA image analysis ....................................................................20 Ultrasound of the ascending aorta .................................................21 Final End-Point Measures .........................................................................23 Cardiac function ............................................................................23 Final heart weight .........................................................................24 Left ventricle histology .................................................................24 Thoracic aorta histology ................................................................25 In vitro vascular function of the MCA ...........................................26 Lipid peroxidation assay ...............................................................27 ii Statistical Analysis ....................................................................................28 III. RESULTS .......................................................................................................29 Weekly Measures ......................................................................................29 Water and tempol intake ................................................................29 Weekly body weight .....................................................................29 Weekly telemetric blood pressure recordings ...............................29 Determination of drug doses for LPCA functional analysis .........31 In vivo vascular analysis of the LPCA .........................................32 Ultrasound of ascending aorta ......................................................34 Final End-Point Measures .........................................................................36 Cardiac function ............................................................................36 Final heart weight .........................................................................37 Left ventricle histology .................................................................37 Thoracic aorta histology ...............................................................38 In vitro vascular function of the MCA ...........................................38 Lipid peroxidation assay ...............................................................39 IV. DISCUSSION .................................................................................................83 Major Findings ...........................................................................................83 Endothelial dysfunction in small resistance-type arteries ..............83 Role of oxidative stress ..................................................................84 Specific cardiac effects of enhanced BPV .....................................89 Specific vascular effects of enhanced BPV ...................................91 Importance of assessing the time course of BPV-induced effects .93 Study Considerations .................................................................................95 Summary and Conclusion .........................................................................96 Perspective and Future Research Directions..............................................97 REFERENCES ................................................................................................................100 iii LIST OF FIGURES Figure 1. Protocol timeline ................................................................................................41 Figure 2. Record of daily water intake...............................................................................42 Figure 3. Weekly changes in body weight .........................................................................43 Figure 4. Weekly telemteric blood pressure values ...........................................................44 Figure 5. Weekly BRS by the sequence technique ............................................................45 Figure 6. Weekly BPV calculated as variance in SBP.......................................................46 Figure 7. Weekly HR derived from the telemetric blood pressure ....................................47 Figure 8. Weekly HRV calculated as SDNN and RMSSD ...............................................48 Figure 9. Description of iris image analysis ......................................................................49 Figure 10. Time needed for maximal LPCA response to corneal application of SNP ......50 Figure 11. LPCA dose response curve to corneal application of SNP ..............................51 Figure 12. Weekly LPCA measures...................................................................................52 Figure 13. Image showing scale of dissected LPCA. ........................................................53 Figure 14. Images of the LPCA during the in vivo vascular function experiment ............54 Figure 15. Weekly LPCA response to pilocarpine ............................................................55 Figure 16. Weekly change in wall area/lumen area ratio in response to pilocarpine ........56 Figure 17. Weekly LPCA response to L-NAME ...............................................................57 Figure 18. Weekly LPCA response to SNP .......................................................................58 Figure 19. Weekly pilocarpine-induced dilation presented as % SNP response ...............59 Figure 20. Description of ultrasound imaging technique of the ascending aorta ..............60 Figure 21. Systolic and diastolic diameter of the ascending aorta .....................................61 Figure 22. Telemetric blood pressure values recorded during ultrasound .........................62 Figure 23. Weekly aortic strain calculated from ultrasound imaging ................................63 Figure 24. Weekly aortic distensibility calculated from ultrasound imaging. ...................64 iv Figure 25. Aortic distensibility measured after nifedipine administration ........................65 Figure 26. Recording of LV and aortic pressure waveform ..............................................66 Figure 27. LV end diastolic pressure .................................................................................67 Figure 28. LV contractility ...............................................................................................68 Figure 29. LV contractility in response to increased afterload ..........................................69 Figure 30. BRS calculated in response to phenylephrine administration ..........................70 Figure 31. Heart weights normalized to body weight ........................................................71 Figure 32. Representative LV sections prepared with Van Gieson’s stain........................72 Figure 33. Representative histology images of the thoracic aorta .....................................73 Figure 34. Thoracic aorta wall thickness ...........................................................................74 Figure 35. Thoracic aorta wall area ...................................................................................75 Figure 36. Thoracic aorta lumen area ................................................................................76 Figure 37. Thoracic aorta wall area/lumen area ratio ........................................................77 Figure 38. Response of the MCA during the in vitro vascular function experiment .........78 Figure 39. Response of the MCA to ACh presented as % of SNP response. ....................79 Figure 40. Correlation of the endothelial-dependent responses of the MCA and LPCA ..80 Figure 41. Lipid peroxidation assay...................................................................................81 Figure 42. Potential pathways linking BPV, ROS, and cardiovascular damage ...............82 v LIST OF ABBREVIATIONS 4-HAE: 4-hydroxyalkenals ACE: angiotensin converting enzyme ACh: acetylcholine Ang II: angiotensin II AT-1: angiotensin II receptor BHT: butylated hydroxytoluene BPV: blood pressure variability BRS: baroreflex sensitivity CaMKII: Ca2+/calmodulin-dependent protein kinase II CRP: C-reactive protein DBP: diastolic blood pressure DDAH2: dimethylarginine dimethylaminohydrolase eNOS: endothelial nitric oxide synthase EPCs: endothelial progenitor cells HR: heart rate HRV: heart rate variability i.p.: intraperitoneal L-NAME: Nω-nitro-L-arginine methyl ester hydrochloride LPCA: long posterior ciliary artery LPO: lipid peroxidation LV: left ventricle LV dP/dtmax: left ventricular contractility LV EDP: left ventricular end diastolic pressure LVW: left ventricle weight vi MAP: mean arterial pressure MAPKs: mitogen-activated protein kinases MCP-1: monocyte chemoattractant protein-1 MDA: malondialdehyde NADPH: nicotinamide adenine dinucleotide phosphate NO: nitric oxide Nox4: NADPH oxidase isoform 4 PP: pulse pressure RAS: renin angiotensin system RMSSD: square root of the mean squared difference of successive normal intervals ROS: reactive oxygen species RVW: right ventricle weight SAD: sinoaortic denervation SBP: systolic blood pressure SBPvar: systolic blood pressure variance SDNN: standard deviation of normal intervals SNA: sympathetic neural activity SNP: sodium nitroprusside TAC: transverse aortic constriction TGF-β: transforming growth factor-beta THW: total heart weight VSMC: vascular smooth muscle cell vii 1 CHAPTER I: INTRODUCTION Background Blood pressure regulatory mechanisms maintain a relatively constant level of mean arterial pressure from day to day; however, blood pressure does fluctuate depending on the time of day, the phase of the respiratory cycle, or in response to physical or psychological stressors. Having chronically elevated mean arterial pressure, or hypertension, is positively associated with pathological changes to the structure and function of the heart and blood vessels. Because of the physiological variation normally seen in blood pressure, it has been suggested that cardiovascular end-organ damage may be more closely associated with the average blood pressure obtained from a long-term (i.e., 24-hour) or continuous mean blood pressure recording than with a single time point measurement (Mancia 1983). In addition to the mean level of blood pressure, the amount of spontaneous variability within the blood pressure is also positively correlated to the severity of organ damage in humans (Parati, Pomidossi et al. 1987; Frattola, Parati et al. 1993). Having an abnormally elevated blood pressure variability (BPV) is considered a cardiovascular risk factor independent of mean arterial pressure (Mancia, Frattola et al. 1994). In spontaneously hypertensive rats chronically treated to lower mean blood pressure, cardiovascular damage was significantly decreased only when BPV was also reduced (Liu, Xu et al. 2003). While it is understood that enhanced BPV is independently associated with damage to multiple organ systems (Mancia, Frattola et al. 1994), the physiological mechanisms involved (hemodynamic, neural, humoral, etc.) remain unclear. 2 Review of Literature Clinical importance of BPV Enhanced BPV in hypertensive humans (Mancia, Ferrari et al. 1983) and animals (Cheng, Kong et al. 1992) has been suggested to result from decreased baroreflex sensitivity (BRS) (Piccirillo, Bucca et al. 1996). The arterial baroreflex represents an important control system, buffering the magnitude of spontaneous blood pressure fluctuations (Mancia, Parati et al. 1986). Reduced BRS can be the result of alterations in the integrity of the autonomic nervous system (Robinson and Carr 2002) as well as endothelial dysfunction (Chapleau, Cunningham et al. 1995). Attenuated baroreflex function following endothelial cell damage is thought to result from a combination of the reduced excitatory influence of prostacyclin as well as the increased formation of free radicals and endothelin which contribute to decreased baroreceptor sensitivity (Chapleau and Abboud 1994). Furthermore, endothelial damage could also reduce nitric oxide release, which is thought to be an additional mechanism for short-term blood pressure control independent of the baroreflex (Stauss and Persson 2000). Additional changes to the mechanical properties of the arterial wall such as vascular calcification and arterial stiffness may also contribute to reduced BRS (Chesterton, Sigrist et al. 2005). The clinical importance of elevated BPV in normotensive populations is highlighted by the many cardiovascular risk factors and diseases that are associated with elevated BPV secondary to reduced BRS, such as aging (Monahan, Dinenno et al. 2001), heart failure (Piccirillo, Nocco et al. 2003), post-myocardial infarction (La Rovere, Bigger et al. 1998), chronic obstructive pulmonary disease (Patakas, Louridas et al. 1982), type II diabetes (Figueroa, Baynard et al. 2007), and chronic renal disease 3 (Johansson, Gao et al. 2007). Of course many additional mechanisms are involved in the organ damage seen in these different clinical populations. It is unclear if enhanced BPV primarily contributes to the cardiovascular end-organ damage in these conditions, or if enhanced BPV occurs secondary as a result of these conditions. However, a negative correlation has been found between baroreflex function and the New York Heart Association heart failure (Rostagno, Felici et al. 1999) classification. This suggests that enhanced BPV may very well contribute primarily to the disease progression or directly contribute to additional organ system damage. The relevance of abnormal blood pressure regulation is further indicated by an association between impaired BRS and cardiac mortality and non-fatal cardiac arrests in patients following myocardial infarction (La Rovere, Bigger et al. 1998). Furthermore, enhanced BPV has been identified as an independent predictor of sudden death in chronic renal failure patients (Johansson, Gao et al. 2007). Finally, in patients with uncomplicated type 2 diabetes, short-term nocturnal BPV significantly predicts negative cardiovascular end-points such as stroke, myocardial infarction, or sudden cardiac death even after adjusting for age, smoking, and the mean level of blood pressure (Eguchi, Ishikawa et al. 2009). Sinoaortic denervation as a normotensive model of BPV Sinoaortic denervation (SAD) is a surgical technique that causes a reduction in BRS by interrupting the neural pathways from the baroreceptors in the carotid bifurcation and the aortic arch to the cardiovascular centers in the brain (Krieger 1964). SAD results in a transient (≤1 week) hypertension and increase in heart rate, but when observed chronically (>1 week), baroreceptor-denervated animals have an average arterial pressure 4 and heart rate that is similar to baroreceptor intact animals (Sved, Schreihofer et al. 1997). The arterial baroreflex deficit associated with SAD is known to significantly elevate BPV and plays an independent and important role in associated end-organ damage observed in SAD animals (Shan, Dai et al. 2001). Multiple mechanisms including hemodynamic, neural, and endocrine mechanisms have been suggested to play a role in the increased variability of arterial pressure observed following SAD. It has been suggested that vascular tone influences BPV in SAD (Julien, Zhang et al. 1993). Increases in peripheral arterial resistance have been demonstrated within the first seven to nine days following SAD but these changes in vascular resistance did not correlate with the changes in BPV (Trapani, Barron et al. 1986). While sympathetic neural activity (SNA) has been shown to be increased in the acute phase (<1 week) of SAD, chronically the average SNA discharge activity normalizes. However, the pattern of discharge activity remains more labile than in sham operated controls, possibly contributing to the increase in BPV (Irigoyen and Krieger 1998). It is likely that the variability seen in arterial pressure following SAD is produced by the interaction of both neural and humoral factors that act on vascular smooth muscle to alter vascular tone (Alper, Jacob et al. 1987). Such a mechanism has been suggested based on experiments using ganglionic blockade which resulted in partial BPV reduction, but only with the additional blockade of the endogenous humoral vasoconstrictors vasopressin and angiotensin did BPV in sinoaortic denervated rats return to control levels (Jacob, Barres et al. 1988). Interestingly, humoral blockade alone did not prevent the SAD-induced increase in BPV, suggesting that neural activity may have a more 5 prominent or a permissive role in determining the severity of blood pressure lability (Jacob, Barres et al. 1988). SAD-induced cardiovascular end-organ damage Cardiac changes following SAD Enhanced BPV following SAD is associated with cardiac hypertrophy determined as increased heart weight normalized to body weight (Miao and Su 2002; Xie, Miao et al. 2003; Zhang, Li et al. 2011). The increase in heart mass may be due to both increased myocyte cross sectional area (Martinka, Fielitz et al. 2005; Takayama, Kai et al. 2011) and increased collagen deposition (Martinka, Fielitz et al. 2005; Tao, Zhang et al. 2008; Flues, Moraes-Silva et al. 2012). These changes have mostly been observed anywhere from 10 to 16 weeks post SAD with the earliest significant increase in left ventricular mass (+11%) demonstrated after only 6 weeks of SAD (Van Vliet, Hu et al. 1996). The cardiac remodeling observed following SAD is associated with elevated left ventricular end-diastolic pressure and decreased myocardial contractility, suggesting a loss of cardiac function observed 10 weeks (Flues, Moraes-Silva et al. 2012) and 12 weeks (Martinka, Fielitz et al. 2005) after SAD. These two studies are the only reports of changes in cardiac function following SAD. It remains unclear if cardiac dysfunction is already present after only 6 weeks of SAD, coinciding with the earliest structural cardiac remodeling observed at this time point (Van Vliet, Hu et al. 1996). Vascular changes following SAD Vascular remodeling following SAD, mainly demonstrated in large conduit arteries, is known to occur in as little as two (Miao and Su 2002) to four weeks (Shen, Zhang et al. 2006). Similar to the heart, vascular changes have been determined as 6 increased vessel weight (Zhang, Li et al. 2011), increased wall thickness (Miao, Tao et al. 2001; Miao, Xie et al. 2002), and increased collagen deposition (Shen, Zhang et al. 2006; Zhang, Li et al. 2011). While these changes have all been demonstrated in the aorta, similar remodeling has also been shown in the pulmonary artery (Tao, Zhang et al. 2008). The pattern of vascular remodeling is different based on the type of vessel. Large conductance-type arteries show an increase in both internal and external vessel diameter suggesting an increase in vascular smooth muscle cell (VSMC) mass. Small resistancetype arterioles respond to enhanced BPV with a different pattern of remodeling characterized as inward remodeling (a decrease in internal diameter) and no change in external diameter (Miao, Tao et al. 2001). This difference between large and small vessel remodeling patterns has also been shown in hypertensive animals and is thought to be due to the functional properties and blood flow patterns experienced in the different vessel types (Mulvany 1999). The inward eutrophic remodeling in resistance-type arterioles may result from a rearrangement of the existing VSMC mass with a proportionally smaller contribution to VSMC growth (Mulvany 1996). While the majority of studies using the SAD model have focused on structural vascular remodeling, there is a paucity of data demonstrating functional vascular changes following SAD, especially in vessels other than the aorta. Vascular relaxation in response to acetylcholine (ACh) but not to sodium nitroprusside (SNP) is reduced after 4 to 16 weeks of SAD in isolated thoracic aorta preparations suggesting endothelial-dependent dysfunction (Miao, Tao et al. 2001; Eto, Toba et al. 2003; Feng, Luo et al. 2011). The reduced endothelial-mediated relaxation may be due to a decrease in the bioavailability of NO as both dimethylarginine dimethylaminohydrolase (DDAH2) and endothelial nitric 7 oxide synthase (eNOS) expressions are decreased significantly in the aortae of SAD rats (Feng, Luo et al. 2011). A decreased aortic distensibility for a given level of arterial pressure occurs at least six weeks post SAD and may be due to an increased aortic wall cross-sectional area, increased collagen content (Lacolley, Bezie et al. 1995), or a decrease in elastin content (Miao, Xie et al. 2002). Interestingly, six weeks of enhanced BPV following SAD surgery did not reduce endothelial-dependent relaxation observed in isolated perfused mesenteric arteries (Van Vliet, Hu et al. 1996). The results of this study would imply that in contrast to the aorta, smaller arteries are somehow protected against the deleterious effects of SAD on endothelial-dependent dilation. Because the process of vascular remodeling is different in vessels of varying sizes it may also be possible that the functional consequences of enhanced BPV differ with respect to the magnitude and/or time course of the response. Mechanisms of SAD induced cardiovascular-end organ damage Renin angiotensin system SAD is associated with increased expression of markers of inflammation, such as cardiac monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-beta (TGF-β), and induction of macrophage infiltration (Kai, Kudo et al. 2009; Takayama, Kai et al. 2011). Additionally, there is increased tissue expression of components of the renin angiotensin system (RAS) while the circulating plasma concentrations remain unchanged following SAD (Shan, Dai et al. 2003; Feng, Luo et al. 2011; Zhang, Li et al. 2011). Treatment with an angiotensin receptor (AT-1) blocker prevents SAD-induced inflammation and cardiovascular end-organ damage. Accordingly, it has been suggested 8 that activation of the cardiac RAS contributes to the pathogenesis of cardiovascular remodeling and dysfunction following SAD (Kai, Kudo et al. 2009). In SAD rats, there is increased endothelial cell apoptosis and degeneration (Shen, Zhang et al. 2006; Feng, Luo et al. 2011). Endothelial progenitor cells (EPCs) preserve the integrity of the endothelium by maintaining the balance between injury and the capacity for repair. Reducing the functional capacity of EPCs through apoptosis can result in a reduction in their ability to maintain the endothelium and ultimately lead to endothelial-dependent dysfunction (Bao, Wu et al. 2010). It has been shown that eNOS expression is significantly decreased in blood vessels of SAD rats (Shen, Zhang et al. 2006; Tao, Zhang et al. 2008; Feng, Luo et al. 2011). This reduction in eNOS has been associated with an increase in apoptotic aortic endothelial cells. The increase in endothelial cell degeneration and reduction in eNOS expression was prevented with the coadministration of losartan (1 μM), an AT-1 receptor antagonist (Feng, Luo et al. 2011), suggesting that activation of cardiac RAS leads to endothelial dysfunction possibly by invoking an increase in endothelial cell apoptosis. In line with these findings, both AT-1 antagonists and angiotensin converting enzyme inhibitors have been used to successfully prevent cardiovascular end-organ damage in SAD rats (Miao, Xie et al. 2002; Xie, Miao et al. 2003; Tao, Zhang et al. 2008). However, RAS-based treatments also prevent any increase in BPV following SAD (Miao, Xie et al. 2002; Xie, Miao et al. 2003; Tao, Zhang et al. 2008). Because the stimulus of enhanced BPV is completely removed it is unclear if there are additional important mechanisms involved in the beneficial effects of RAS inhibition. 9 Mitogen activated protein kinases Enhanced BPV following SAD is characterized by an increase in the number of high pressure episodes and low pressure episodes without a change in the mean level of blood pressure. It is thought that the increase in blood pressure fluctuations activate mechanosensitive and autocrine pathways that result in the aforementioned cardiovascular remodeling and dysfunction (Martinka, Fielitz et al. 2005). While there is a large number of potential signal transduction pathways, the family of mitogen-activated protein kinases (MAPKs), which include p38 MAPK, ERK1/2, and others, has been implicated as critical mechanosensitive regulators involved in cardiovascular end-organ damage (Molkentin 2004). Furthermore, MAPKs have been shown to be activated in the SAD model of enhanced BPV (Martinka, Fielitz et al. 2005; Takayama, Kai et al. 2011). The importance of the involvement of MAPKs has been recently shown by treating SAD rats with simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase inhibitor. Simvastatin attenuated myocyte hypertrophy and this change was related to a reduction in ERK1/2 expression (Takayama, Kai et al. 2011). The authors did not observe any reduction in myocardial fibrosis, macrophage infiltration, or the expression of TGF-β or MCP-1 suggesting only a partial involvement of ERK1/2. Nonetheless, this study is important because it is the only one that demonstrates a reduction in cardiovascular endorgan damage in a treatment protocol that did not reduce the SAD-induced increase in BPV. However, it also demonstrates the need to further investigate the mechanisms involved in SAD-induced cardiovascular end-organ damage. In addition to its cholesterol lowering effects, simvastatin is thought to possess antioxidant properties (Delbosc, Cristol et al. 2002). Interestingly, nicotinamide adenine dinucleotide phosphate (NADPH) 10 oxidases have been shown to produce reactive oxygen species (ROS) that lead to the phosphorylation and thereby activation of p38 MAPK (Griendling and Ushio-Fukai 2000). The results of these previous studies further implicate the family of MAPKs as important intracellular messengers and imply that oxidative stress may act to mediate MAPK involvement in SAD-induced cardiovascular end-organ damage. Oxidative stress AngII is known to play an important role in the development of cardiac hypertrophy (Baker, Chernin et al. 1990), interstitial cardiac fibrosis (Tokuda, Kai et al. 2004), and left ventricular dysfunction (Schunkert, Dzau et al. 1990). Emerging evidence indicates that ROS are important signaling molecules in cardiovascular cells and are involved in transducing many of the effects of AngII such as mediating the activation of important intracellular signals, such as p38 MAPK (Griendling and Ushio-Fukai 2000). ROS have been linked to cardiac hypertrophy in response to both AngII (Nakamura, Fushimi et al. 1998) and mechanical stretch (Pimentel, Amin et al. 2001). NADPH oxidase has also been shown to contribute to the development of angiotensin II-induced cardiac hypertrophy, independent of changes in blood pressure (Bendall, Cave et al. 2002). ROS can also be generated in the blood vessels and are regulated by hormonesensitive enzymes such as the NADPH oxidases. Incubation of VSMC (Griendling, Minieri et al. 1994) and aortic fibroblasts (Pagano, Chanock et al. 1998) with AngII has been shown to induce production of ROS such as superoxide in these cells. As stated above, a main function of ROS is to act as second messengers to activate multiple intracellular proteins and enzymes which initiate signaling cascades leading to induction 11 of transcription factors involved in VSMC growth and migration, modulation of endothelial-dependent relaxation, and modification of the extracellular matrix (Griendling, Sorescu et al. 2000). For example, in endothelial cells it has been shown that overexpression of NADPH oxidase isoform 4 (Nox4) enhances the phosphorylation of p38 MAPK (Goettsch, Goettsch et al. 2009). Increased activation of p38 MAPK can lead to enhanced EPC apoptosis (Bao, Wu et al. 2010) and has been implicated in the pathogenesis of a variety of cardiovascular diseases (Wang 2007). As second messengers, ROS can also modulate ion channels increasing intracellular free Ca2+ concentration, a major determinant of vascular function (Touyz 2004). Conditions associated with elevated circulating levels of AngII, such as enhanced BPV, may contribute to increased superoxide production via activation by NADPH oxidases and thus may benefit by antioxidant treatment (Rajagopalan, Kurz et al. 1996) with compounds such as tempol. Tempol as a potential treatment option Effects of tempol on the heart Tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine) is a water soluble, membranepermeable superoxide dismutase mimetic that mainly acts as a free radical scavenger but may also contribute to activating potassium channels or inhibiting the sympathetic nervous system (Simonsen, Christensen et al. 2009). Two weeks of tempol administration in the drinking water (1 mMol/L) has been shown to reduce oxidative stress in vivo and significantly decrease mean arterial pressure (MAP) in spontaneously hypertensive rats (SHR) (162 ± 8 to 134 ± 6 mmHg) without altering MAP in Wistar Kyoto normotensive rats (WKY) (115 ± 5 vs. 118 ± 8 mmHg) (Schnackenberg, Welch et al. 1998). In rats with chronic AngII infusion, Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) 12 attenuated tempol-mediated anti-hypertensive effects and improved regional hemodynamic control (Nishiyama, Fukui et al. 2001) suggesting that AngII-induced oxidative stress inactivates NO (Yang, Li et al. 2011). Tempol has not previously been used to treat sinoaortic denervated animals. It, therefore, remains unknown if tempol will reduce enhanced BPV following SAD as is the case with other treatment options, such as angiotensin converting enzyme (ACE) inhibitors (Tao, Zhang et al. 2008). Several studies in other disease models of enhanced tissue RAS-induced oxidative stress suggest a beneficial effect of tempol in preventing cardiac remodeling and dysfunction (Hasegawa, Takano et al. 2006; Yagi, Akaike et al. 2010; Rizzi, Castro et al. 2011). Tempol also effectively reduced cardiac end-organ damage in mice on a highfructose diet subjected to transverse aortic constriction (TAC), also known as aortic banding, for eight weeks (Chess, Xu et al. 2008) and in a diabetic murine model without aortic banding (Ritchie, Quinn et al. 2007). In contrast, tempol did not reduce cardiac hypertrophy despite reducing the cardiac tissue superoxide concentration in a rat model of AngII-induced hypertension (Rugale, Delbosc et al. 2007) or in mice subjected to TAC for four weeks prior to the start of tempol treatment (Moens, Takimoto et al. 2008). As stated previously, ROS are known to activate cardiac MAPK signaling pathways leading to cardiac hypertrophy and fibrosis. Tempol has been shown to effectively and completely eliminate increased phosphorylation of MAPKs while preventing both cardiac hypertrophy and fibrosis in the diabetic myocardium (Gurusamy, Watanabe et al. 2006). In another study, tempol prevented cardiac fibrosis but did not reduce the enlarged cardiac mass in chronic isoproterenol-infused rats (Zhang, Kimura et al. 2005). Because of the discrepancies observed in previous studies the role of tempol in preventing cardiac 13 remodeling remains unclear. The results suggest that tempol treatment can prevent cardiac fibrosis and may be able to prevent the onset of cardiac hypertrophy depending on the study conditions but is less likely to successfully reverse a pre-existing pathologic increase in cardiac mass. Effects of tempol on the vessels Similar to the heart, enhanced oxidative stress has been suggested to contribute to vascular remodeling (Dikalova, Clempus et al. 2005). Accordingly, tempol treatment decreases oxidative stress resulting in at least a partial reversal of vessel wall hypertrophy while increasing luminal area (DeMarco, Habibi et al. 2008). Hypertension is associated with increased amounts of ROS in the aortic wall which results in VSMC growth, increased collagen deposition, and impairment of endothelial function thought to be due to reduced NO bioavailability (Zicha, Dobesova et al. 2001; Castro, Rizzi et al. 2009; Simonsen, Rodriguez-Rodriguez et al. 2009). Aging is also associated with marked endothelial dysfunction that is mediated by ROS (Modrick, Didion et al. 2009; Trott, Seawright et al. 2011; Fleenor, Seals et al. 2012). In both hypertensive and older animals, eNOS activity was restored and the vascular response to ACh was improved with chronic tempol treatment (Modrick, Didion et al. 2009; Durand, Moreno et al. 2010). Additionally, tempol reduces large artery stiffening by normalizing arterial collagen deposition (Fleenor, Seals et al. 2012). As with the heart, there is evidence for a RAS/oxidative stress-induced MAPK signaling cascade in blood vessels. A transgenic rat model (TG(mRen2)27), which harbors the mouse renin transgene and has elevated tissue AngII levels exhibits increased NADPH oxidase activity resulting in greater endothelial cell apoptosis and deactivation 14 of eNOS (Wei, Whaley-Connell et al. 2007). The importance of oxidative stress in this model is exemplified by the normalization of apoptosis and eNOS activation following tempol treatment. Furthermore, an association between ROS and p38 MAPK was demonstrated by introducing elevated levels of C-reactive protein (CRP) into coronary arteries (Blaschke, Bruemmer et al. 2004). CRP is known to increase as part of the immune systems inflammatory response and is thought to be involved in cellular apoptosis. Incubating arteries with CRP results in superoxide-mediated endotheliumdependent dysfunction (Blaschke, Bruemmer et al. 2004). This detrimental effect of CRP on NO-mediated vasodilation can be prevented by treatment with tempol, the NADPH oxidase inhibitor apocynin, or the p38 MAPK inhibitor SB203850 (Qamirani, Ren et al. 2005), suggesting p38 MAPK is intricately involved in oxidative stress signaling pathways including those involved in NO bioavailability. Purpose of Study The hypothesis of this study is that SAD leads to increased production of ROS, which mediate the subsequent cardiovascular remodeling and dysfunction. The specific aims of this project will be to first determine the extent of cardiovascular remodeling and dysfunction in response to enhanced BPV secondary to a partial loss of baroreflex sensitivity. Unique to this project, we will be using an in vivo repeated measures technique to determine the time course of changes in vascular function in small arterioles and the ascending aorta. Secondly, we will investigate the role that oxidative stress may play in SAD-induced cardiovascular end-organ damage by chronic administration of tempol in the drinking water to prevent the accumulation of ROS. 15 Despite multiple published studies characterizing the cardiovascular end-organ damage following SAD in normotensive rats, the pathogenesis remains unknown. While the previous studies investigating SAD all tend to demonstrate similar findings, the time course of SAD-induced cardiovascular end-organ damage is largely unknown. Previous studies have used either a single end-point measurement (commonly at 2, 6, 10, 12, or 16 weeks) or were investigating changes at different weeks but still utilizing end-point measurements obtained in different groups of animals for each time point. To my knowledge, this project is the first to utilize repeated in vivo measures within the same animal to determine the time course of cardiovascular end-organ damage following SAD. Additionally, it remains to be seen if endothelial-dependent function is reduced in small arteries or arterioles as BPV-induced endothelial-dysfunction has only previously been observed in the thoracic aorta. Furthermore, antioxidant treatments have not been investigated with regards to end-organ damage in response to enhanced BPV. The evidence presented in the introduction to this thesis presents a strong case for an important role of oxidative stress, possibly activated by the local tissue RAS, in the cardiovascular end-organ damage observed following SAD. 16 CHAPTER II: METHODS Experimental Design Animals All experiments were performed on 8-week-old male, normotensive Sprague Dawley rats (Harlan Laboratories, Haslett, MI). Rats had free access to a standard rat chow diet and drinking water. Rats were housed in a temperature (24±2°C), humidity (60±10%), and 12-hour light cycle (lights on: 0600-1800) controlled environment. All experiments have been approved by the Institutional Animal Care and Use Review Committee at The University of Iowa. Experimental protocol The experimental protocol is illustrated in Figure 1. At an age of eight weeks, in vivo imaging of the iris and ultrasound echocardiography were completed to determine baseline conditions of vascular structure and function of the long posterior ciliary artery (LPCA) and the ascending aorta, respectively. After baseline values were obtained, normotensive Sprague Dawley rats had a telemetric blood pressure sensor implanted and underwent either SAD surgery to induce an increase in BPV or a sham surgery to serve as controls with normal BPV. The sinoaortic denervated rats were divided into untreated (SAD) or tempol-treated groups (SAD+Tempol). The SAD+Tempol group received chronic administration of tempol (1mMol/L, ~21mg·kg body weight-1·day-1) via the drinking water throughout the entire time course of the protocol, starting immediately after the SAD surgery was completed. The water bottles containing the tempol solution were wrapped with aluminum foil because tempol is light sensitive. The tempol solution was replaced three times per week. During the six-week observation period, blood 17 pressure (radio-telemetry) was recorded and in vivo imaging of the iris and ultrasound imaging of the ascending aorta were performed once per week in all animals of all three groups. After the six-week observation period, additional in vivo and in vitro end-point parameters of cardiac and vascular structure and function were obtained. Surgical procedures Rats were anesthetized using isoflurane (~2% isoflurane in room air) throughout all surgical procedures. A telemetric blood pressure sensor (TA11PA-C40; Data Sciences, St. Paul, MN) was implanted with the tip of the catheter inserted into the abdominal aorta and fixed into position at a level caudal to the renal arteries. SAD surgery was performed bilaterally by exposing both common carotid arteries through a midline incision in the neck region, removing the adventitia from each carotid bifurcation and brushing its branches with a 10% phenol solution (phenol diluted with 70% ethanol). Medial to the vagus nerve, the aortic depressor nerve was identified and sectioned bilaterally. The laryngeal nerve that also contains aortic baroreceptor fibers was not cut. This procedure is consistent with a complete carotid sinus denervation and a partial aortic baroreceptor denervation. Thus, the BRS in the SAD rats is expected to only be partially reduced thereby more closely mimicking the condition observed in elderly populations and those with chronic diseases (Ketch, Biaggioni et al. 2002). For the control group, a sham operation was performed by exposing each carotid artery but without applying phenol and without cutting any nerves. Survival rate following SAD was ~69% while it was 100% in the sham operated control group. This mortality rate is similar to what has been previously reported for animals undergoing SAD surgery (Van Vliet, Chafe et al. 18 1999; Miao and Su 2002). The cause of mortality was related to respiratory complications, with death occurring during surgery or within five days following surgery. Weekly Measures Telemetric blood pressure recording Starting one week after SAD or sham surgery, weekly telemetric blood pressure recordings were obtained throughout the six-week observation period. Blood pressure was recorded for approximately one hour during the middle of the day (between the hours of 1000-1400) while the rats were minimally active or resting. Average heart rate (HR), systolic blood pressure (SBP), mean arterial pressure (MAP), and diastolic blood pressure (DBP) were derived from the blood pressure waveform recordings. Systolic blood pressure variance (SBPvar) and baroreflex sensitivity (sequence technique) were calculated using the freely available Hemolab software (http://www.haraldstauss.com/HemoLab/HemoLab.html) to confirm successful SAD surgery. Additionally, time domain measures of heart rate variability (HRV) were also calculated using the Hemolab software. Weekly in vivo vascular analysis of the LPCA The LPCA in the iris of the left eye of each rat was photographed through a slitlamp biomicroscope (model FS-2; Nikon Instruments, Melville, NY) using a 30x objective lense and a Canon 50D (15 megapixels) digital camera (see Figure 9). To increase optical resolution, a 3x teleconverter was inserted between the slit-lamp and the digital camera, resulting in a final optical magnification of 90x and a final digital image resolution of 0.53 µm/pixel. To obtain maximal image quality the camera was operated at the highest resolution and highest quality setting, and the images were stored in lossless Tagged Image File format. All of the imaging procedures were done in conscious rats 19 manually held in front of the slit-lamp biomicroscope by one investigator while a second investigator operated the slit-lamp and the digital camera. The methods for this procedure and some of the preliminary experiments were part of a separate study that has previously been published (Stauss, Rarick et al. 2011). Determination of drug doses for LPCA functional analysis In preliminary experiments, the time needed to elicit the maximal vasodilator response following corneal drug application for pilocarpine (1% Pilocarpine Hydrochloride Ophthalmic Solution, Falcon Pharmaceuticals, Fort Worth, TX) and SNP (Sigma Aldrich) were determined. These experiments were performed on a separate group of eight-week-old Sprague Dawley rats that were not used otherwise for the chronic study. Iris imaging was carried out on different days to avoid drug interactions and to allow time for the rats to recover. Thirty microliters of each drug solution was applied on the cornea after a baseline image of the LPCA was taken. Subsequently, images of the LPCA were taken every 2-3 min for approximately 30-45 minutes depending on how long the dilator response was visible. After determining the time required for each drug to elicit its maximal response, a dose response curve was constructed for each drug. After a baseline image of the LPCA was taken, the lowest dose of the drug was applied to the cornea, and after waiting the necessary amount of time to obtain the maximal response a second set of images was taken. This procedure was then repeated for each subsequent higher dose. This allowed for determination of the lowest concentration of each drug that would still elicit a maximal vasodilation. In similar experiments, the necessary dose of L-NAME needed to effectively inhibit pilocarpine- 20 induced vasodilation was determined. Briefly, a baseline image was taken and then the LPCA was pretreated with one of several concentrations (0%, 1%, 2%, or 4%) of the NOsynthase inhibitor L-NAME (Sigma-Aldrich, St. Louis, MO). Five minutes after corneal application of one of the L-NAME concentrations, pilocarpine was administered on the cornea and after waiting 10 minutes (time point of maximum response) images of the LPCA were taken to determine if pilocarpine administration was still able to elicit a vasodilatory response if the LPCA was pre-treated with the respective dose of L-NAME. Endothelial dependent/independent dilation of the LPCA Before application of any drugs, initial images of the LPCA were taken in order to determine baseline vascular parameters that served as a reference for determining the changes elicited by corneal application of the different drugs. First, to determine endothelial-dependent dilation, a pilocarpine solution (30 µl, 1% solution in sterile saline) was applied to the cornea and after waiting approximately 10 minutes for drug absorption and action a second set of images was taken. Next, in order to block endogenous NO production an L-NAME solution (30 µl, 4% solution in sterile saline) was instilled on the cornea and a third set of images was taken after waiting approximately 10 minutes. Finally, endothelium-independent maximal vasodilation of the LPCA was determined by applying the exogenous NO donor SNP (30 µl, 0.1M diluted in 0.9% sterile saline) to the cornea before a fourth set of images was taken. LPCA image analysis The photographs of the LPCA were analyzed using the image processing software, Imager, which is included with the freely available HemoLab software package 21 (http://www.haraldstauss.com/HemoLab/HemoLab.html). This software visualizes the images such that each pixel within the digital photograph is displayed at exactly one pixel of the computer screen, thus avoiding scaling or interpolation and providing the highest possible image resolution for data analysis. Using a crosshair cursor, the investigator marks four points in perpendicular orientation to the longitudinal axis of the artery. Two of the four points mark the outer edges of the vessel wall and two points mark the inner edges of the vessel wall corresponding to the lumen of the artery. Based on these four points the Imager software calculates the cross-sectional area of the artery (calculated as an area of a circle with the diameter determined by the outer edges of the vessel wall) and the lumen area (calculated as an area of a circle with the diameter determined by the inner edges of the vessel wall). The Wall/Lumen ratio is then calculated as W/L ratio = [(area of the artery – area of the lumen)/area of the lumen]. For each image, 10 measurements are taken, and the average of the 10 measurements is used for statistical analysis (see Figure 9). Ultrasound of the ascending aorta Weekly ultrasound imaging (7.5 MHz linear-array transducer; ultrasound model CMS600B-3; Contec Medical Systems, Qinhuangdao China) was performed to assess the time course of changes in vascular parameters of the ascending aorta following SADinduced increase in BPV. Imaging was performed with the rats under isoflurane anesthesia (~2% in room air). The ascending aorta was imaged using a motion mode (Mmode) recording in the parasternal long-axis with the rat in the lateral decubitus position. The M-mode image was analyzed in order to assess the systolic and diastolic diameters of the ascending aorta using the Imager software (HemoLab software; 22 http://www.haraldstauss.com/HemoLab/HemoLab.html, see Figure 20). While the Mmode images were being taken, the telemetric blood pressure signal was simultaneously recorded to obtain the aortic pulse pressure (Pressuresystole – Pressurediastole). The measured diameters and pulse pressure were then used to calculate the aortic strain and aortic distensibility as previously described by Stefanadis et al. (Stefanadis, Dernellis et al. 2000) using the following two equations: 1. Aortic Strain = [(systolic diameter – diastolic diameter)/diastolic diameter] 2. Aortic Distensibility = (2*Strain/pulse pressure) Aortic strain and distensibility are commonly used as indices of aortic stiffness. The aortic strain provides a measure of how much the aortic diameter increases in systole compared to diastole. Aortic distensibility normalizes the aortic strain by the pulse pressure to allow for comparison across groups that may have differences in their distending pressures (such as SAD vs. Sham). A stiffer aorta, as experienced with age or atherosclerosis, would be expected to have lower values for aortic strain and distensibility when compared to a more compliant aorta. Additionally, in a small subset of animals (SAD n=2; SAD+Tempol n=3) a second set of images were taken after intraperitoneal (i.p.) administration of the calcium channel blocker nifedipine (5 mg/kg body weight) in order to assess the aortic diameter under physiologic vascular tone (without nifedipine) as well as in a relaxed vascular state (with nifedipine). The maximal response of the i.p. nifedipine injection occurred within ~2 minutes at which point the M-mode image of the ascending aorta was taken. The telemetric blood pressure signal was also recorded during the imaging following nifedipine administration. 23 Final End-Point Measures Cardiac function Following completion of the six-week observation period, cardiac diastolic and systolic function were determined by measuring left ventricular end diastolic pressure (LV EDP) and left ventricular contractility (LV dP/dtmax), respectively. Experiments were performed while the rats were anesthetized (~2% isoflurane in room air). A 23-gauge needle-tipped, heparinized-saline filled catheter was inserted through the chest wall into the left ventricle (LV). Placement of the catheter inside the LV was verified by visual observation of the characteristic left ventricular pressure waveform. Once the catheter was in place and flushed with heparinized-saline, a 10-minute baseline recording of the LV pressure signal was obtained. After the baseline recording, intravenous bolus injections of the selective α1-adrenergic receptor agonist phenylephrine (0.5ml of 10µg·ml-1) were given to determine changes in LV EDP and LV dP/dtmax following an increase in cardiac afterload caused by elevated total peripheral resistance and mean arterial pressure. Phenylephrine injections were repeated three times to verify the response. LV pressure was allowed to return to baseline before each subsequent injection. The Analyzer program (HemoLab software; http://www.haraldstauss.com/HemoLab/HemoLab.html) was used to calculate LV EDP and LV dP/dtmax on a beat-by-beat basis as described in the Hemolab manual. LV EDP was determined using the zero-crossing of the second derivative of the LV pressure waveform as a trigger. See Figure 26 for a representative pressure waveform and heart rate recording during this experiment. 24 Final heart weight Following completion of the left ventricular pressure experiment, rats were deeply anesthetized using isoflurane (~5% isoflurane in room air) and euthanized by exsanguination and subsequent removal of the heart. Blood was withdrawn by cardiac puncture, collected into heparinized tubes, and immediately centrifuged (2000g for 20 minutes) at 4°C for separation of the plasma which was then flash frozen in liquid nitrogen and stored at -80°C until analyzed. Upon removal, the hearts were placed into cold (4°C) Krebs-Henseleit solution (D-Glucose 2.0g/L, Magnesium Sulfate 0.141g/L Potassium Phosphate Monobasic 0.16g/L, Potassium Chloride 0.35g/L, Sodium Chloride 6.9g/L, Calcium Chloride 0.29g/L, and Sodium Bicarbonate g/L) and immediately dissected by removal of any remaining vasculature or connective tissue, and any blood or fluid from within the ventricles. The atria were removed before the total heart weight (THW) which included only the left and right ventricles was measured and recorded. The right and left ventricles were then separated; the left (LVW) and right (RVW) ventricles were weighed, and both ventricles were stored for further analyses. The right ventricle was kept whole and wrapped in aluminum foil and flash frozen in liquid nitrogen. The left ventricle was further dissected into the base and apex. The base of the left ventricle was freshly embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA) and slowly frozen in liquid nitrogen for histological analysis while the apex was wrapped in aluminum foil and flash frozen in liquid nitrogen for biochemical analysis. Left ventricle histology The base or superior half of the left ventricle, which was freshly embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA), 25 frozen in liquid nitrogen, and stored at -80°C was allowed to equilibrate to -20°C in a freezer for 24 hours and then mounted in a microtome (model 855; American Optical Scientific Instruments, Buffalo, NY) at -20°C. Three consecutive transverse sections (20 µm) starting from the middle of the left ventricle and working towards the base were mounted on glass slides that had been coated with gelatin. The slides were then processed with Van Gieson’s stain to differentiate the cardiac muscle tissue which stains yellow from the connective tissue which stains pink (See Figure 32 for representative sections). Three fields of vision (10x magnification) of each ventricular section were imaged using a color camera (TCA-5.0) mounted on a microscope (Olympus CKX41). The images were taken of both the free wall and the septal wall and were assessed via ImageJ software (National Institutes of Health, Public Domain, Bethesda, MD). The percent area of connective tissue per field was determined by using the ImageJ Threshold Color plugin which allows for the selection and measurement of pixel area based on color differences. Thoracic aorta histology After the rats were euthanized, the thoracic aorta was excised and placed in a small dissecting dish filled with cold (4°C) Krebs-Henseleit solution (Sodium Chloride 6.9g/L, Magnesium Sulfate 0.141g/L Potassium Phosphate Monobasic 0.16g/L, Potassium Chloride 0.35g/L, and Sodium Bicarbonate g/L without glucose and calcium chloride). The thoracic aorta was dissected free of any remaining connective tissue and gently flushed to remove any blood and then placed in a 10% neutral buffered formalin fixative for histological analysis. Once fixed, the thoracic aortas were embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA) and 26 mounted in a microtome (model 855; American Optical Scientific Instruments, Buffalo, NY) at -20°C. Approximately five consecutive cryosections (40 µm) were obtained for analysis starting immediately at the point where the aortic arch was dissected from the thoracic aorta. This ensured that the same section of each vessel was analyzed for each rat. The sections were stained with Van Gieson’s stain (See Figure 33 for representative sections) and imaged using a digital camera mounted on an inverted microscope. The wall and lumen cross-sectional areas were determined using the ImageJ software (National Institutes of Health, Public Domain, Bethesda, MD), and morphological parameters were calculated. In vitro vascular function of the MCA After the rats were euthanized, the proximal section of the middle cerebral artery (MCA) was removed from the brain in a small dissecting dish filled with cold (4°C) Krebs-Henseleit solution (D-Glucose 2.0g/L, Magnesium Sulfate 0.141g/L Potassium Phosphate Monobasic 0.16g/L, Potassium Chloride 0.35g/L, Sodium Chloride 6.9g/L, Calcium Chloride 0.29g/L, and Sodium Bicarbonate g/L) bubbled with 95% O2/5% CO2 gas. The excised segment of the MCA was then moved to a vessel chamber containing the same gassed Krebs-Henseleit solution that was warmed to 37°C. The MCA was attached by silk suture material (7-0) to glass pipette cannulae and pressurized to 90 mmHg for all experiments. The viability of the vessel was determined by verifying that it responded to changes in pressure and constricted in the presence of a high potassium Krebs-Henseleit solution. The vessel was allowed to equilibrate for 30 minutes in the regular potassium Krebs-Henseleit solution before any experiments were started. The MCA was pre-constricted (~30% of the baseline diameter) by administration of 27 vasopressin (concentration = 1x10-10 to 1x10-11M) and allowed to re-equilibrate for another 30 minutes. Under the continuous presence of vasopressin, an ACh dose response curve (1x10-7 to 1x10-3 M) was performed to determine the endothelial-dependent function. The endothelial-independent function was also determined by measuring the response to a maximal dose of SNP (1x10-3M). In a small group of rats (SAD: N=3; Sham: N=2), the above experiments were repeated in the presence of tempol (1x10-3M, Sigma Aldrich) to determine if endothelial function would be restored following pretreatment with the superoxide dismutase mimetic. In this experiment, the vessel was again pre-constricted with vasopressin and allowed to equilibrate for 30 minutes with the addition of tempol before the ACh dose response curve was repeated. Lipid peroxidation assay Frozen cardiac tissue samples from the ventricles were analyzed to determine the tissue concentration of malondialdehyde (MDA) and 4-hydroxyalkenals (4-HAE) as an indicator of lipid peroxidation and oxidative stress. Separate samples from the right and left ventricle from each rat were analyzed to determine if there is a differential oxidative stress-induced lipid peroxidation within the heart. A 100-mg tissue sample was weighed and homogenized in 1 ml of ice-cold phosphate buffered saline solution (PBS, 20 mM, pH 7.4) containing 10 µl 0.5 M butylated hydroxytoluene (BHT) in acetonitrile. The homogenate was then centrifuged at 5000g for 10 minutes at 4°C. The supernatant was removed and used for determination of MDA and 4-HAE as described in the commercially available LPO-586 colorimetric assay kit (OXIS Health Products, Burlingame, CA). Samples were read at 586 nm in a spectrophotometer (Biomate 3, Thermo Electron Corporation, Madison, WI) and results are presented as lipid 28 peroxidation concentration per mg of protein. Protein concentration was determined from a separate aliquot of each tissue homogenate sample using a colorimetric protein assay (Bio-Rad Laboratories, Hercules, CA). Statistical Analysis A one-way ANOVA design of independent measures was used for single timepoint comparisons made between the three groups. A two-way ANOVA design of independent/repeated measures was used to compare differences between the three groups for any weekly repeated measures. Differences were considered significant at p < 0.05. When significant differences were observed in the ANOVA comparisons, post hoc testing (Tukey HSD) was done to determine which groups or time-points contributed to the significant differences. Pearson correlation coefficient was calculated to determine linear dependence between sets of two variables. The calculated r value was considered significant if equal to or greater than published critical values of r at α = 0.05. All data are presented as Means ± SEM. Error bars used in the figures also represent the SEM. 29 CHAPTER III: RESULTS Weekly Measures Water and tempol intake All rats had free access to a standard rat chow diet and drinking water. Food intake was not monitored for any study group. Water intake was only monitored in the SAD+Tempol group in order to determine the amount of tempol received during the study (see Figure 2). Water intake remained relatively constant during the study with an average value of 12.3 ± 0.7 ml/100 g body weight/day. With chronic administration of tempol in the drinking water at a concentration of 1mMol/L, treated rats received ~6.4 ± 0.1 mg tempol/day or ~21 ± 1 mg/kg body weight/day. Weekly body weight Body weight was not significantly different between the three study groups at any point during the study (see Figure 3). There was a time effect for all three groups to gain weight each week during the study due to normal growth with the exception of week 1 (weight taken 1 week post-surgery) which was not different from week 0 (weight taken the day of surgery). The lack of a weight gain in week 1 was most likely related to the surgical procedures. Weekly telemetric blood pressure recordings A 30-minute section from each weekly telemetric BP recording was used to derive SBP, MAP, DBP, and HR. Compared to sham surgery, SAD resulted in a mild and non-significant elevation of arterial blood pressure at week one after surgery (SBP: Sham = 121 ± 3 mmHg; SAD = 131 ± 2 mmHg; SAD+Tempol = 135 ± 15 mmHg) (MAP: Sham = 102 ± 2 mmHg; SAD = 110 ± 2 mmHg; SAD+Tempol = 114 ± 15 mmHg) (DBP: 30 Sham = 84 ± 2 mmHg; SAD = 92 ± 2 mmHg; SAD+Tempol = 97 ± 15 mmHg). Thereafter, no differences in BP were found between the three groups (see Figure 4). The BRS calculated from SBP and pulse interval was significantly greater in the Sham group compared to the SAD and SAD+Tempol groups during each week of the study. This finding indicates successful baroreceptor denervation. BRS demonstrated a time effect with a minimal sensitivity observed in the week immediately following surgery, followed by a slight increase in weeks 2 - 3 and stable values from week 3 - 6 (see Figure 5). The greatest BRS gains were seen at week 6 in all groups and were still significantly (p < 0.05) lower in the denervated groups (SAD = 1.1 ± 0.05 ms/mmHg; SAD+Tempol = 1.1 ± 0.07 ms/mmHg) compared to the control group (Sham = 1.6 ± 0.1 ms/mmHg). In line with the decreased BRS observed in the sinoaortic denervated groups, BPV calculated as SBPvar was significantly increased in SAD and SAD+Tempol compared to the Sham group during the six week observation period (see Figure 6). Initially at week 1, SBPvar observed in the denervated groups was ~4 to 5 fold greater than in the Sham group. BPV tended to decrease over the six week observation period in the denervated groups but was still 2 to 3 fold greater at week 6 in the SAD and SAD+Tempol groups compared to the Sham group. Notably, there was no significant difference in either BRS or SBPvar between the tempol-treated and non-treated SAD groups. Similar to the BP values, HR tended to be slightly elevated at week 1 in SAD (402 ± 13 bpm) and SAD+Tempol (380 ± 14 bpm) compared to Sham (358 ± 12 bpm) but there were no significant differences between the three groups at any time point 31 throughout the study. However, there was a time effect with week 1 HR values being greater than the values at weeks 2 – 6 (see Figure 7). Measures of HRV were also not significantly different between the three groups (see Figure 8). However, a time effect was observed for SDNN (standard deviation of normal intervals) with the first two weeks being lower than weeks three to six (p < 0.05 vs. week one and two). RMSSD (square root of the mean squared difference of successive normal intervals) also demonstrated a time effect with weeks five and six being greater than week one (p < 0.05 vs. week one). The pattern of lower overall HRV (SDNN) and lower vagally-mediated HRV (RMSSD) immediately after surgery was most prevalent in the untreated SAD group. Determination of drug doses for LPCA functional analysis The results of the pilocarpine and L-NAME experiments have been previously published (Stauss, Rarick et al. 2011). All experiments were conducted in normotensive Sprague Dawley rats. It was determined that a single corneal application of a 30-µl bolus of a 1% pilocarpine solution resulted in a maximal vasodilator response within ~10 minutes. Pretreatment with corneal application of 30 µl of a 4% L-NAME solution was able to prevent any significant increase in LPCA lumen diameter in response to the 1% pilocarpine solution, suggesting that pilocarpine-mediated vasodilation of the LPCA is mainly mediated by endothelial NO release. In the current study we wanted to include the exogenous NO donor SNP to differentiate between endothelial-dependent and independent vasodilator responses of the LPCA. The time to maximal vasodilation in response to corneal application of a 30 µl bolus of a 0.01 M SNP solution was found after ~10 minutes (n = 2, see Figure 10). A dose response curve for SNP identified the 32 maximal vasodilator response of the LPCA at a dose of 30 µl of a 0.1 mM solution (n = 2, see Figure 11). At this dose the LPCA lumen diameter increased by 68 ± 7%. Increasing the concentration to 1 M SNP did not result in any further dilation of the LPCA (+58 ± 12%). In vivo vascular analysis of the LPCA The structural vascular parameters (wall thickness, lumen diameter, wall area/lumen area ratio) of the LPCA were determined each week prior to the application of any drugs. These values were then used as the baseline measures to determine the change elicited by application of the experimental drugs (pilocarpine, L-NAME, and SNP) to normalize for different starting lumen diameters. There were no significant changes in the structural vascular parameters over the six week observation period for any of the three groups compared to their respective pre-surgery values. Wall thickness, wall area, lumen diameter, and lumen area were not significantly different between any of the three groups pre-surgery or during the six week observation period. However, there was a group effect for the wall area/lumen area ratio to be significantly increased in the SAD+Tempol (1.05 ± 0.02) group compared to Sham (0.91 ± 0.02) and SAD (0.92 ± 0.01) due to the tendency for SAD+Tempol to have a smaller lumen area throughout the study. For all three groups, the lumen diameter and lumen area were significantly smaller when imaged pre-surgery compared to weeks four, five, and six (see Figure 12). Figure 13 shows the wall thickness and lumen diameter in an isolated, unpressurized LPCA. This LPCA was excised from the iris muscle of a Sprague Dawley rat in order to compare the wall thickness and lumen diameter of an isolated vessel with the values calculated from the slit-lamp images. The isolated, unpressurized LPCA had a wall thickness of 8 to 10 µm and a lumen diameter 33 ranging from 35 to 40 µm, confirming the values obtained by in vivo imaging of the LPCA utilizing the slit-lamp. This confirmation is important because it demonstrates that the in vivo imaging is not affected by a potential magnifying effect of the cornea. Functional vascular parameters were assessed as the change in LPCA lumen diameter in response to corneal application of pilocarpine, L-NAME, and SNP (see Figure 14). The dilatory response to pilocarpine was significantly different between the three groups and demonstrated a time dependent decrease in the two denervated groups compared to the sham group that was lessened with tempol treatment. Endothelialdependent dilation in response to pilocarpine was significantly reduced in the SAD group (p < 0.05 vs. Sham) from week three to six. In tempol-treated SAD rats, the LPCA response to pilocarpine was significantly less than in Sham rats at week one, three, and six, but was still significantly greater than the SAD group at the end of the six week observation period (see Figure 15). Similar to the change in lumen diameter, the calculated wall area/lumen area ratio determined after corneal application of pilocarpine significantly increased over time in the SAD group compared to the other two groups starting at week three (see Figure 16). Notably, there was no difference between the sham-operated control rats and tempol-treated SAD rats in this parameter. The wall area/lumen area ratio was not different between the three groups following corneal application of SNP (data not shown), indicating that the pilocarpine-induced response was not due to a structural change in the vascular wall or to altered function of the VSMCs. Following the pilocarpine-induced vasodilation, corneal application of L-NAME resulted in a similar lumen diameter in all three groups that was not significantly different 34 from the baseline lumen diameters measured prior to the application of any drugs (see Figure 17). This finding indicates that there is very little (if any) endogenous basal NO release in the LPCA of rats. There was no change in the vasoconstrictor response of the LPCA to L-NAME during the six week observation period in any of the three groups. The vasodilatory response to SNP was not significantly different between any of the three groups during any week of the study (see Figure 18). However, the endothelialindependent dilation of the LPCA in response to SNP demonstrated a time dependent effect and was lower at weeks 1 and 2 compared to the pre-surgery value (p < 0.05). This initial reduction in the SNP response was only significant in the two denervated groups. During the baseline measures taken pre-surgery, all three groups demonstrated a similar dilatory response to pilocarpine and SNP. The pilocarpine-induced dilation expressed as a percentage of the SNP-induced response was significantly reduced in the untreated SAD group (p < 0.05 vs. Sham and SAD+Tempol) starting at week three but not until week six in the tempol treated SAD group (p < 0.05 vs. Sham). At week six, the pilocarpine-induced dilation in both denervated groups was ~20% lower than the dilation seen after corneal application of SNP (Sham: 98.4 ± 2.8%; SAD: 81.1 ± 3.5 %; SAD+Tempol: 84.9 ± 2.2) (see Figure 19). Ultrasound of ascending aorta Diameters of the ascending aorta during systole (Sham = 2.18 ± 0.03 mm; SAD = 2.07 ± 0.03 mm; SAD+Tempol = 1.99 ± 0.01 mm) and diastole (Sham = 1.68 ± 0.02 mm; SAD = 1.83 ± 0.02 mm; SAD+Tempol = 1.63 ± 0.02 mm) did not differ among the three groups (see Figure 21). The average telemetric blood pressure values, simultaneously measured during the ultrasound imaging, were also not significantly different between the 35 three groups (SBP: Sham = 125 ± 1 mmHg; SAD = 127 ± 2 mmHg; SAD+Tempol = 120 ± 3 mmHg) (DBP: Sham = 81 ± 1 mmHg; SAD = 84 ± 2 mmHg; SAD+Tempol = 78 ± 1 mmHg), see Figure 22. Pulse pressure, which was used to calculate aortic distensibility, was similar between the three groups except during week 1 when it was significantly lower in the SAD+Tempol group (p < 0.05 vs. Sham and SAD). At the beginning of the protocol (pre-surgery) aortic strain was similar in the SAD and Sham groups. Immediately starting one week after SAD surgery and persisting throughout the observation period, the untreated SAD group demonstrated a significantly reduced aortic strain compared to the Sham-operated animals (p < 0.05). The SAD+Tempol group demonstrated a time-dependent change in aortic strain. One week after denervation surgery, tempol-treated SAD rats had a significantly reduced aortic strain (p < 0.05 vs. Sham) that temporarily improved during weeks two and three before again significantly decreasing for the final three weeks of the study. Aortic strain in the SAD+Tempol group never decreased to the same extent as the untreated SAD group as it was still significantly greater even at week 6 (p = 0.03 vs. SAD) (see Figure 23). Aortic distensibility was significantly decreased at all six weeks in the SAD group when compared to the Sham group. In contrast, aortic distensibility in the SAD+Tempol group was only significantly decreased at week five and six compared to the Sham group. Tempol treatment not only delayed the onset of blunted distensibility but also reduced the overall loss of aortic distensibility as compared to the untreated SAD group (see Figure 24). In a small subset of denervated rats (SAD: n = 2; SAD+Tempol: n =3) aortic distensibility was also determined following the administration of the calcium channel blocker nifedipine. In the absence of endogenous vascular tone due to calcium channel 36 blockade, the beneficial effect of tempol on aortic distensibility was no longer observed (see Figure 25). This finding may indicate that the beneficial effect of tempol on aortic distensibility is mediated through an effect on basal vascular tone. Statistics were not run on the changes in aortic distensibility following nifedipine administration due to the small sample size for each group. Final End-Point Measures Cardiac function Six weeks after SAD surgery, LV EDP was significantly increased in both untreated and tempol treated rats compared to the Sham group (p < 0.05) during resting baseline conditions measured while the rats were under anesthesia. Following the baseline recording, intravenous injections of phenylephrine were given to increase cardiac afterload. All three groups had a similar increase in LV EDP in response to the increased afterload. LV EDP measured during the peak increase in blood pressure was significantly higher in the untreated SAD group, but not in the tempol-treated SAD group when compared to the Sham group (see Figure 27). LV contractility (LV dP/dtmax) was similar in all three groups during the baseline recording as well as during the peak increase in blood pressure following phenylephrine injection. In response to phenylephrine injection, the untreated SAD group only increased LV dP/dtmax by 980.4 ± 181.7 mmHg/s compared to increases of 1437.9 ± 284.6 mmHg/s for the Sham group and 1332.0 ± 166.1 mmHg/s for the SAD+Tempol group. However, these delta values were not significantly different between the groups (see Figures 2829). 37 SBP and HR were derived from the aortic pressure waveform recorded during the cardiac function analysis. BRS was calculated from the change in HR divided by the change in SBP in response to phenylephrine injection. Both the untreated and tempoltreated SAD rats had a significantly decreased BRS compared to the Sham group (p < 0.05, see Figure 30). These observations of BRS taken at the end of the study further confirm the BRS results calculated by the sequence technique from the weekly telemetric blood pressure recordings in conscious rats. Final heart weight Six weeks of SAD resulted in significant cardiac hypertrophy as indicated by the total weight of the heart normalized to body weight (Sham = 0.246 ± 0.008 g heart tissue/g body weight*100; SAD = 0.281 ± 0.005 g heart tissue/g body weight*100; SAD+Tempol = 0.265 ± 0.009 g heart tissue/g body weight*100). SAD also demonstrated a significant increase in the weight of the LV while there was only a trend (p = 0.09) for the weight of the RV to be increased compared to the sham group (see Figure 31 for heart weights normalized to body weight). Total heart weight for the SAD+Tempol group was not significantly different from either the Sham (p = 0.08) or SAD group (p = 0.1). Similar tendencies were observed in the LV of the tempol-treated group, whereas the weight of the RV was similar to the SAD group (p = 0.9) but tended to be greater than the Sham group (p = 0.09). Left ventricle histology There was a trend for SAD to result in an increase in the percent area of connective tissue in the wall of the left ventricle (see Figure 32). In seven of the ten SAD rats there was a significant increase in connective tissue area that was 30 ± 2% greater 38 than the Sham group (n = 8), while three of the SAD rats had a percent area that was lower than the Sham group. This variability caused the overall group averages to not be significantly different. All six of the tempol-treated SAD rats had a similar percent area of connective tissue in the LV wall compared to the Sham group (10 ± 1 % area for both groups). Thoracic aorta histology Representative images of the thoracic aorta prepared with Van Gieson’s stain are presented in Figure 33. Histology sections of the thoracic aorta revealed a significant increase in the wall thickness and wall area following six weeks of SAD (p < 0.05 vs. Sham). The increase in wall size, due to hypertrophy of the tunica media, was partially prevented by chronic administration of tempol. In the SAD+Tempol group, the average wall thickness was significantly less than in the untreated SAD group (88.9 ± 4.0 µm vs. 99.4 ± 2.5 µm); however, the wall area (Sham: 0.44 ± 0.03 mm2; SAD: 0.55 ± 0.02 mm2; SAD+Tempol: 0.50 ± 0.03 mm2) tended to demonstrate some hypertrophy and was not significantly different from either Sham (p = 0.17) or SAD (p = 0.15). Lumen areas of the thoracic aortae did not differ between the three groups. Consequently, the wall area/lumen area ratio followed the results observed for the wall area measures (see Figures 34-37). In vitro vascular function of the MCA Figure 38 shows the absolute lumen diameters of the MCA in the isolated microvessel experiments. The baseline lumen diameters after the vessels were pressurized and allowed to equilibrate were similar in all three groups (~125 µm) as were the vasopressin pre-constricted lumen diameters (~70% of baseline, vasopressin 10-10 to 39 10-11 M). In the untreated SAD group there was impaired endothelial-dependent dilation in response to increasing doses of ACh (p < 0.05 vs. Sham). The loss of endothelialdependent function was almost fully prevented by chronic tempol treatment (SAD+Tempol) with only the highest ACh dose eliciting a decreased response compared to the Sham group. Endothelial-independent vascular function assessed by the response to a maximal dose of SNP was not significantly different between any of the three groups. The ACh-induced dilation of the MCA expressed as a percentage of the maximal SNP response is presented in Figure 39. Only the Sham group had a maximal ACh– induced dilation that was not significantly less than the SNP induced response (Sham: 92.3 ± 2.6 %; SAD: 27.7 ± 4.0 %; SAD+Tempol: 65.8 ± 4.5 %). Chronic tempol treatment significantly improved endothelial function by significantly increasing the dilatory response to all but the lowest dose of ACh administered compared to the untreated SAD group. There was a significant correlation observed between the maximal ACh-induced dilation in the isolated MCA and the pilocarpine-induced dilation obtained in week 6 from the in vivo imaging of the LPCA in a pooled sample of individual rats from all three groups (see Figure 40). The in vitro measures of vascular function in the MCA (lumen diameter ~125 µm) confirm the results observed in the weekly in vivo imaging of the LPCA (lumen diameter ~40 µm) and provide additional evidence of SAD-induced endothelial-dependent dysfunction in small arteries and arterioles. Lipid peroxidation assay The tissue concentration of MDA and 4-HAE was determined in the left and right ventricles as an indicator of oxidative stress. There was a trend for the combined tissue 40 concentration of MDA+4-HAE to be increased in the untreated SAD group in both ventricles (LV: p = 0.09; RV: p = 0.068). Tempol treatment prevented this trend for an increase in the measured indicators of oxidative stress. In rats from all three groups, lipid peroxidation normalized for total protein content was significantly greater in the LV compared to the RV (see Figure 41). 41 Figure 1. Protocol timeline and list of experiments performed at each time point. Baseline measures were completed at an age of 8 weeks. Rats were randomized into three groups and surgeries were performed the following week. The first of six weekly measurements were taken approximately seven days following the completion of the surgical procedures. The end-point measures were then taken in the seventh week post-surgery, at an age of 16 weeks. 42 Water Intake (ml/100g/day) 30 24 18 12 6 0 Tempol (mg/kg/day) 40 30 20 10 0 0 1 2 3 4 Time (weeks) 5 6 7 Figure 2. Average daily water intake (top) and amount of tempol received (bottom) in the SAD+Tempol group throughout the experimental protocol. Week 0 = week of surgery; Week 1-6 = 6 week observation period; Week 7 = week of end-point measurements. 43 Sham SAD SAD+Tempol 500 Body Weight (g) 400 * * * * * * 6 7 300 200 100 0 0 1 2 3 4 Time (weeks) 5 Figure 3. Change in body weight during the study starting the week of surgery (week 0). There was no difference in body weight between the three groups. * p < 0.05 vs. week 0 for all three groups. 44 Sham SAD SAD+Tempol SBP (mmHg) 150 120 90 60 30 0 MAP (mmHg) 150 120 90 60 30 DBP (mmHg) 0 150 120 90 60 30 0 1 2 3 4 Time (weeks) 5 6 Figure 4. Blood pressure values derived from the weekly telemetric aortic pressure waveform recordings. Values were not significantly different between the three groups at any time point. 45 Sham SAD SAD+Tempol BRS gain (ms/mmHg) 2 1.6 1.2 * * 0.8 * * * * # # # # 3 4 Time (weeks) 5 6 0.4 0 1 2 Figure 5. Baroreflex sensitivity measured by the sequence technique using weekly one hour telemetric blood pressure recordings. The Sham control group had a higher baroreflex gain compared to both the untreated and tempol-treated SAD groups. * p < 0.05 SAD and SAD+Tempol vs. Sham. # p <0.05 vs. week one. 46 Sham SBP variance (mmHg2) 160 SAD SAD+Tempol * * 120 * * 80 # * * 5 6 40 0 1 2 3 4 Time (weeks) Figure 6. BPV calculated as the variance of SBP was greater in SAD and SAD+Tempol compared to Sham (* p < 0.05). # p <0.05 week six vs. week one. 47 Sham SAD SAD+Tempol 500 # HR (bpm) 400 # # # 3 4 Time (weeks) 5 # 300 200 100 0 1 2 6 Figure 7. HR was not significantly different between the three groups during the study but tended to be elevated in the two denervated groups at week 1 compared to the Sham group. A time effect was observed with HR being significantly greater in week one than in weeks two through six (# p < 0.05). 48 Sham 15 SAD # SAD+Tempol # # # 12 SDNN (ms) 9 6 3 0 8 # RMSSD (ms) 6 # 4 2 0 1 2 3 4 Time (weeks) 5 6 Figure 8. Measures of HRV demonstrate a time effect for SDNN with the first two weeks being lower than week three to six (# p < 0.05 vs. week one and two). RMSSD also demonstrated a time effect with week one being less than week five and six (# p < 0.05 vs. week one). 49 Figure 9. Image displaying the four branches of the LPCA in the iris of a Sprague Dawley rat (top panel). The lower right branch in the iris of the left eye was used for imaging. The bottom panel shows a representative analysis using Imager (Hemolab software) to place ten sets of four markers on the wall and lumen borders. 50 80 70 Lumen diameter (um) 60 50 40 30 20 10 0 BL 5 10 15 20 25 Time (minutes) 30 35 40 Figure 10. Preliminary experiment determining the time to maximum vasodilatory response of the LPCA to SNP. Maximal vasodilation of the LPCA was seen around 10 minutes after corneal application of the SNP dose (30 µl of 0.01 M solution). 51 90 80 Lumen diameter (um) 70 60 50 40 30 20 10 0 00 -5 .00001 10 -4 1E-04 10 -3 1E-03 10 -2 1E-02 10 -1 1E-01 10 11 Dose (M) Figure 11. SNP dose response curve to determine the minimal dose needed to elicit a maximum vasodilatory response of the LPCA. Maximal vasodilation of the LPCA was obtained with corneal application of the 30 µl 0.1M SNP dose. Wall Thickness (µm) 52 Sham 10 SAD SAD+Tempol 8 6 4 2 0 Wall Area/Lumen Area Ratio Lumen Diameter (µm) 50 # # # 4 5 # 40 30 20 10 0 1.5 1.2 0.9 0.6 0.3 0 BL 1 2 3 Time (weeks) 6 Figure 12. Weekly imaging of the LPCA taken before the application of any drugs. Wall thickness (top) and lumen diameter (middle) were not different between any of the groups at any point during the study. There was a time effect for the lumen diameter before surgery to be smaller than during week 1, 4, 5, and 6 (# p < 0.05 vs. BL). Wall area/lumen area ratio (bottom) demonstrated a group effect with SAD+Tempol being significantly greater than SAD and Sham (p <0.05). BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 53 Figure 13. Isolated section of the LPCA from a Sprague Dawley rat. The LPCA was removed from the iris and placed on a glass slide in saline solution and imaged at a magnification of 40x to verify the wall and lumen values obtained with the slit-lamp imaging technique. Wall thickness and lumen diameter values were comparable between the images and the isolated vessel. 54 Baseline Pilocarpine L-NAME SNP Figure 14. Successive images taken of the same section of the LPCA in the iris of a conscious rat using a slit-lamp biomicroscope before (Baseline, top left) and after corneal application (30 µL) of the muscarinic agonist pilocarpine (top right), L-NAME (bottom left), and SNP (bottom right). 55 Sham SAD SAD+Tempol ΔLumen Diameter (um) 30 25 20 * 15 10 * 5 * * *† 0 BL 1 2 3 Time (weeks) 4 *† 5 *† 6 Figure 15. Change in lumen diameter from baseline (before any drug application) in response to corneal application of pilocarpine. The LPCA response to pilocarpine was significantly different between the three groups and demonstrated a time dependent decrease in the two denervated groups that was lessened with tempol treatment. *p < 0.05 vs. Sham, †p < 0.05 SAD vs. SAD+Tempol. BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 56 W/L ratio (% change from BL) Sham SAD SAD+Tempol 40 * 30 * * * 20 10 0 -10 -20 BL 1 2 3 Time (weeks) 4 5 6 Figure 16. Data presented are for the wall area/lumen area ratio measured after corneal application of pilocarpine over the course of the study and normalized to the pre-surgery value (BL). The wall area/lumen area ratio significantly increased over time in the SAD group compared to the other two groups (* p <0.05 vs. Sham and SAD+Tempol). BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 57 Sham SAD SAD+Tempol 10 ΔLumen Diameter (um) 8 6 4 2 0 -2 -4 -6 -8 -10 BL 1 2 3 Time (weeks) 4 5 6 Figure 17. Change in lumen diameter from baseline (before any drug application) in response to corneal application of L-NAME. There were no significant differences between the three groups. BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 58 Sham SAD SAD+Tempol ΔLumen Diameter (um) 30 25 20 15 10 *# 5 * # 0 BL 1 2 3 Time (weeks) 4 5 6 Figure 18. Change in lumen diameter from baseline (before any drug application) in response to corneal application of SNP. There were no significant group effects for the LPCA response to SNP. There was a time effect for the average of all three groups to be lower at weeks 1 and 2 compared to BL (p < 0.05). p < 0.05 *SAD weekly comparison with BL value; #SAD+Tempol weekly comparison with BL value. BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 59 Sham SAD SAD+Tempol Pilocarpine Induced Dilation (%of SNP response) 140 120 100 80 *† 60 *# *† 40 20 0 BL 1 2 3 4 Time (weeks) 5 6 Figure 19. Pilocarpine-induced dilation of the LPCA presented as a percentage of the vasodilatory response to exogenous NO. Endothelial-dependent dilation was impaired at three weeks after SAD surgery. Tempol treatment resulted in improved endothelialdependent dilation and delayed the loss of endothelial-dependent function until week 6. *p < 0.05 SAD vs. Sham, †p < 0.05 SAD vs. SAD+Tempol, #p < 0.05 SAD+Tempol vs. Sham. BL = week before surgery, 1-6 = the six week observation period starting one week after surgery. 60 Figure 20. Echocardiography image displaying the left ventricle in the parasternal long axis (left) and the associated M-mode tracing (right). The trigger line (dotted white line) marking the location of the ascending aorta used for the M-mode tracing is denoted by a black arrow in the left panel. Determined from the M-mode tracing, the lumen diameter of the ascending aorta was measured during systole (black marker) and during diastole (white marker). 61 Sham SAD SAD+Tempol Systolic Diameter (um) 0.3 0.25 0.2 0.15 0.1 0.05 0 Diastolic Diameter (um) 0.3 0.25 0.2 0.15 0.1 0.05 0 1 2 3 4 Time (weeks) 5 6 Figure 21. Weekly ultrasound measures of the lumen diameter of the ascending aorta during systole (top panel) and diastole (bottom panel) were not different between the three groups during the six week observation period that started one week post-surgery. 62 Sham SAD SAD+Tempol 3 4 Time (weeks) 5 SBP (mmHg) 150 120 90 60 30 0 DBP (mmHg) 100 80 60 40 20 Pulse Pressure (mmHg) 0 60 50 40 30 20 * 10 0 1 2 6 Figure 22. Telemetric blood pressure was simultaneously recorded during the weekly ultrasound imaging of the ascending aorta. Blood pressure values for SBP (top) and DBP (middle) were not different between the three groups during the six week observation period that started one week post-surgery. Pulse pressure (bottom) was significantly decreased in the SAD+Tempol group only at week 1 (* p < 0.05 vs. SAD and Sham). 63 Sham SAD SAD+Tempol Strain [(sysø - diaø)/diaø] 0.4 0.32 # 0.24 # # # 0.16 * 0.08 *† *† *† *† *† 5 6 0 BL 1 2 3 4 Time (weeks) Figure 23. Weekly ultrasound measures of aortic strain were similar pre-surgery (BL) but then significantly decreased immediately one week following denervation surgery in both the untreated and tempol-treated rats. Aortic strain stayed reduced in the untreated SAD rats (* p < 0.05 SAD vs. Sham; † p < 0.05 SAD vs. Sad+Tempol), but was temporarily restored by tempol treatment before partially decreasing in later weeks (# p <0.05 SAD+Tempol vs. Sham). sysø = lumen diameter during systole. diaø = lumen diameter during diastole. 64 Sham SAD SAD+Tempol Aortic Distensibility (mmHg-1) 0.02 0.016 0.012 # # *† *† 5 6 0.008 0.004 * *† 1 2 *† *† 0 3 4 Time (weeks) Figure 24. Weekly ultrasound measures of aortic distensibility were significantly decreased throughout the six week observation period in the SAD group (* p < 0.05 SAD vs. Sham; † p < 0.05 SAD vs. Sad+Tempol), but was temporarily prevented by tempol treatment before partially decreasing in later weeks (# p <0.05 SAD+Tempol vs. Sham). Aortic distensibility was not determined at baseline (pre-surgery) because the rats were not yet instrumented with telemetric blood pressure sensors; therefore, pulse pressure could not be measured. 65 SAD +Nif Aortic Distensibility (mmHg-1) 0.020 SAD+Tempol +Nif 0.016 0.012 0.008 0.004 0.000 1 2 3 4 Time (weeks) 5 6 Figure 25. Administration of the calcium channel blocker nifedipine was able to restore aortic distensibility in the SAD group (n = 2) to the level of the SAD+Tempol group making it similar to the Sham group for the first four weeks of the six week observation period. In the SAD+Tempol group (n = 3), nifedipine only improved the week one response. Nifedipine restored aortic distensibility in the untreated SAD rats to the level of distensibility in the tempol-treated SAD rats. 66 SBP HR Figure 26. Example of LV (red tracing) and aorta (blue tracing) pressure waveforms recorded to determine the LV dP/dtmax and LV EDP after the six week protocol. Pressure was recorded before and after intravenous administration of phenylephrine (0.5 ml, 10 µg/ml) to determine changes in cardiac function following an increase in afterload. SBP and HR were derived from the aortic pressure waveform to determine BRS in response to phenylephrine injection. 67 Baseline Phenylephrine 40 # * LV EDP (mmHg) 32 24 * * 16 8 0 Sham SAD SAD+Tempol Figure 27. After six weeks of denervation, LV EDP was significantly greater in both SAD groups compared to the Sham group during the baseline recording before phenylephrine injection. Whereas during phenylephrine-induced increase in cardiac afterload LV EDP was significantly higher in only the untreated SAD rats compared to Sham-operated rats (*p < 0.05 vs. Sham). LV EDP was significantly increased by phenylephrine injection in all rats (# p < 0.05 phenylephrine vs. baseline). 68 Baseline Phenylephrine LV dP/dtmax (mmHg/s) 9000 # 7500 6000 4500 3000 1500 0 Sham SAD SAD+Tempol Figure 28. After six weeks of denervation, LV dP/dtmax was similar between all groups during the baseline recording before as well as after phenylephrine injection. All groups demonstrated a similar increase in LV EDP following the increase in afterload (# p < 0.05 phenylephrine vs. baseline). 69 1800 Δ LV dP/dtmax (mmHg/s) 1500 1200 900 600 300 0 Sham SAD SAD+Tempol Figure 29. LV contractility tended to have a smaller increase in response to phenylephrine injection in SAD compared to Sham (p = 0.14) following six weeks of denervation. The tendency for this loss of contractility was not seen in tempol treated rats. 70 ΔHR/ ΔSBP (bpm/mmHg) 1.2 0.9 * * SAD SAD+Tempol 0.6 0.3 0.0 Sham Figure 30. BRS as calculated from the ratio of change in HR to change in SBP following phenylephrine injection was similarly decreased following six weeks of SAD in both untreated and tempol-treated groups (* p < 0.05 vs. Sham). 71 (THW/BW)*100 0.30 * 0.27 0.24 0.21 0.18 0.15 (LVW/BW)*100 0.25 * 0.22 0.19 0.16 0.13 0.10 (RVW/BW)*100 0.07 0.06 0.05 0.04 0.03 0.02 Sham SAD SAD+Tempol Figure 31. Total heart weight (top) and left ventricular weight (middle) normalized to body weight were significantly increased in SAD vs. Sham (*p < 0.05) but not when compared to SAD+Tempol. Tempol treatment tended to partially prevent cardiac hypertrophy (THW: p = 0.08 vs. Sham; LV: p = 0.18 vs. Sham). Right ventricular weight normalized to body weight for the SAD group tended to be increased vs. Sham (p = 0.09). SAD+Tempol was not significantly different from either group (p = 0.99 vs. SAD; p = 0.2 vs. Sham). 72 Sham SAD SAD+Tempol Figure 32. Representative histology sections of the left ventricle prepared with Van Gieson’s stain to differentiate cardiac muscle (pale yellow color) from connective tissue deposition (pink color). There was a trend for a greater percent area of connective tissue in the untreated SAD group compared to Sham and the SAD+Tempol groups. 73 Sham SAD SAD+Tempol Figure 33. Representative sections of the thoracic aorta prepared with Van Gieson’s stain. The hypertrophic changes (increased wall thickness and wall area) seen with increased BPV (SAD) were prevented by tempol treatment (SAD+Tempol). 74 120 * Wall Thickness (µm) 100 80 60 40 20 0 Sham SAD SAD+Tempol Figure 34. Wall thickness of the thoracic aorta was significantly increased in SAD (*p < 0.05 vs. Sham and SAD+Tempol). Tempol treatment limits the increase in wall thickness in response to increased BPV (p = 0.13 vs. Sham). 75 0.6 * Wall Area (mm2) 0.5 0.4 0.3 0.2 0.1 0 Sham SAD SAD+Tempol Figure 35. Wall area of the thoracic aorta was significantly increased in SAD (*p < 0.05 vs. Sham). In the SAD+Tempol group, wall area tended to be greater than that of the Sham group (p = 0.17) but was less than that of the SAD group (p = 0.15). Tempol treatment limits the increase in wall area in response to increased BPV. 76 2.5 Lumen Area (mm2) 2 1.5 1 0.5 0 Sham SAD SAD+Tempol Figure 36. Lumen area of the thoracic aorta was not different between the three experimental groups. 77 0.30 Wall Area/Lumen Area ratio * 0.24 0.18 0.12 0.06 0.00 Sham SAD SAD+Tempol Figure 37. The wall area/lumen area ratio of the thoracic aorta was significantly increased in SAD compared to the Sham group (*p < 0.05). In the SAD+Tempol group, wall area/lumen area ratio tended to be greater than in the Sham group (p = 0.2) but also tended to be less than the SAD group (p = 0.17). Tempol treatment limits the extent of aortic hypertrophy in response to increased BPV. 78 Sham SAD SAD+Tempol Lumen diameter (µm) 175 150 125 # 100 * 75 * * * * 50 25 0 -7 -7 -6 -6 -5 -5 -4 -4 -3 1x10 3x10 1x10 3x10 1x10 3x101x10 3x10 1x10 Drug Dose (M) Figure 38. Response (absolute lumen diameter) of the middle cerebral artery to increasing doses of ACh (10-7 to 10-3 M) and to a maximal dose of SNP (10-3 M) following preconstriction with vasopressin (VP, 10-10 to 10-11 M). Increased BPV (SAD) resulted in a blunted endothelial-dependent dilation (*p < 0.05 vs. Sham and SAD+Tempol) but in no change in the endothelial-independent response. Tempol treatment almost completely prevented the loss of endothelial-dependent function (# p < 0 .05: SAD+Tempol vs. Sham). 79 SAD SAD+Tempol 100 80 60 40 20 * 0 -7 1x10 -7 3x10 * * * -6 1x10 -6 -5 * * -5 # # # -4 3x10 1x10 3x10 1x10 * Lumen diameter (% SNP response) Sham * -4 3x10 -3 1x10 Drug Dose (M) Figure 39. Response (expressed as a % of the maximal SNP-elicited dilation) of the middle cerebral artery to increasing doses of ACh (10-7 to 10-3 M) following preconstriction with vasopressin (VP, 10-10 to 10-11 M). Increased BPV (SAD) resulted in a blunted endothelial-dependent dilation (*p < 0.05 vs. Sham and SAD+Tempol) that was only 30% of the maximal response seen with the application of exogenous NO. Tempol treatment was able to partially restore the endothelial-dependent dilation to 66 % of the maximal SNP-elicited response (# p < 0 .05: SAD+Tempol vs. Sham). 80 90 y = 2.8833x + 15.116 R² = 0.6172 MCA Δ lumen diameter (µm) 80 70 60 50 40 30 20 10 0 0 5 10 15 LPCA Δ lumen diameter (µm) 20 25 Figure 40. There was a significant correlation (r = 0.8; p < 0.01 @ dfn-2 = 17, r =.575) between the maximal endothelial-dependent response of the MCA to ACh (y-axis) and the week six endothelial-dependent response of the LPCA to pilocarpine (x-axis). Each data point represents an individual rat. Rats from all three groups are pooled for the correlation analysis. 81 LV RV MDA + 4-HAE (nM/mg protein) 1.60 1.40 1.20 # 1.00 0.80 0.60 SAD+Tempol SAD Sham 0.40 0.20 0.00 Sham SAD SAD+Tempol Figure 41. There was a trend for increased oxidative stress as measured by lipid peroxidation in the left (p = 0.09) and right (p = 0.068) ventricles of SAD rats compared to Sham rats. Tempol administration prevented any increase in oxidative stress (SAD+Tempol vs. Sham: p = 0.99 for LV, p = 0.965 for RV). Indicators of lipid peroxidation were significantly greater in the LV compared to the RV (p < 0.05). 82 Figure 42. Diagram demonstrating how cardiovascular end-organ damage resulting from increased BPV can potentially be mediated through oxidative stress-dependent and oxidative stress-independent mechanisms. 83 CHAPTER IV: DISCUSSION Major Findings There are two major novel findings of this study: First, we have demonstrated that enhanced BPV causes a time-dependent reduction in endothelial-dependent dilation in small resistance type arteries. Second, BPV-induced cardiovascular end-organ damage can be ameliorated by chronic antioxidant treatment with the superoxide dismutase mimetic tempol. These new findings are important because endothelial dysfunction of small resistance-type arteries can have deleterious effects on regulation of microcirculatory blood flow in vascular beds such as the cardiac and cerebral circulation and contribute to development of secondary diseases, such as hypertension, coronary heart disease, heart failure, or stroke. Finally, the beneficial effect of chronic antioxidant treatment on BPV-induced cardiovascular end-organ damage provides important mechanistic insights into the pathogenesis of BPV-associated cardiovascular morbidity and mortality. Endothelial dysfunction in small resistance-type arteries While it has been demonstrated previously that enhanced BPV causes endothelial dysfunction in large conduit arteries, such as the aorta (Miao, Tao et al. 2001; Eto, Toba et al. 2003; Feng, Luo et al. 2011), the experiments described in this set of studies unequivocally show that BPV-induced endothelial dysfunction also affects smaller resistance-type arteries (LPCA = 40 µm; MCA = 125 µm). The small resistance vessels of the microcirculation largely determine local tissue blood flow and total peripheral resistance (DeLano, Schmid-Schonbein et al. 1991). Increased peripheral resistance implies a narrowing of the resistance vessels which would occur with either structural 84 remodeling resulting in a reduction in lumen diameter (Mulvany 2012) or a functional change, such as endothelial dysfunction (Deng, Li et al. 1995), resulting in greater vascular tone. The ability of resistance vessels to appropriately alter vascular tone in response to changes in blood flow/shear stress is essential to maintain adequate tissue perfusion for nutrient and metabolic waste exchange as well as to protect smaller downstream vessels from potentially damaging high blood flows. In the current study, there was a progressive reduction in endothelial-dependent dilation without any evidence for endothelial-independent dysfunction or structural remodeling of the LPCA. This finding is in line with studies demonstrating that functional microvascular impairment may act in a permissive manner to induce structural remodeling. A similar progression from functional microvascular disturbances to structural vascular remodeling has been observed in both diabetes and hypertension and may be associated with increasing severity of the underlying disease (Levy, Schiffrin et al. 2008). For example, a reduction in cerebral blood flow leads to energy depletion in neural cells and is thought to trigger a cascade of events from inflammatory responses to ischemic stroke (Danton and Dietrich 2003). Similarly, impaired myocardial perfusion may lead to localized ischemia resulting in impaired cardiac function and the development of heart failure or the potential to provoke serious arrhythmias (Kaufmann and Camici 2005). Interestingly, reperfusion of ischemic tissue can lead to accumulation of ROS which are known to further exacerbate cardiovascular disease as will be described in the next section. Role of oxidative stress This study demonstrated for the first time that chronic antioxidant treatment using the superoxide dismutase mimetic tempol prevents or ameliorates BPV-induced 85 cardiovascular end-organ damage. Specifically, tempol reduced the deleterious effects of BPV on aortic stiffness (strain and distensibility) and aortic hypertrophy (wall to lumen ratio) as well as cardiac function (LV EDP and LV dP/dtmax) and cardiac hypertrophy (THW/BW and LVW/BW ratios and LV collagen deposition). Furthermore, tempol treatment almost completely prevented endothelial dysfunction in small resistance arteries (LPCA and MCA). Importantly, the reduction in cardiovascular end-organ damage observed with tempol treatment occurred without a reduction in the elevated BPV or without improving the blunted baroreflex sensitivity following baroreceptor denervation. Thus, the mechanisms of cardiovascular protection from BPV by tempol do not include reduction of BPV or improvement of BRS. These findings provoke two important questions: First, which mechanisms and/or pathways link elevated BPV with increased oxidative stress? Second, which mechanisms and/or pathways link oxidative stress with cardiovascular end-organ damage? Regarding the first question, while a direct cause and effect relationship has yet to be defined there are several potential mechanisms linking elevated BPV with increased oxidative stress. First, activation of the RAS is considered a major pro-oxidant neurohormonal system that is over activated in cardiovascular disease (Dhalla, Temsah et al. 2000). Importantly, RAS activation has been demonstrated in models of chronic SAD (Miao, Xie et al. 2002; Shan, Dai et al. 2003). Recently, SAD-induced elevated BPV has been shown to increase the aortic tissue content of both AngII and the lipid peroxidation by-product MDA, suggesting an association between activation of the RAS and increased oxidative stress (Feng, Luo et al. 2011). A second potential mechanism would be related to mechanosensitive or stress activated pathways. Oxidative stress can be a physiological 86 consequence of working cardiac muscle (Erickson, He et al. 2011). ROS are known to be derived from the mitochondria at several points within the electron transport chain during oxidative phosphorylation (Andreyev, Kushnareva et al. 2005). ROS production can also be induced by mechanical stimuli such as shear stress, pulsatile strain, and stretch (Lassegue and Clempus 2003). Once they are activated, ROS have been shown to induce activation of multiple kinases and transcription factors through oxidation reactions (Touyz, Tabet et al. 2003). Thus, increased BPV may create a greater mechanical stimulus resulting in the accumulation of ROS. The increased oxidative stress would then mediate the downstream activation of mechanosensitive second messengers such as members of the MAPK family that have been demonstrated to be upregulated following SAD (Martinka, Fielitz et al. 2005; Takayama, Kai et al. 2011). Finally, periods of coronary ischemia/reperfusion may also result in accumulation of oxidative stress. While SAD animals are considered to be normotensive (Norman, Coleman et al. 1981), the higher BPV results in brief hypertensive as well as hypotensive episodes. Although it is not clear if these brief hypotensive episodes are severe enough to result in myocardial ischemia, the related changes in blood pressure and coronary flow could result in periods of coronary hypo-perfusion. While ROS are normally formed during mitochondrial respiration, it has been reported that ischemia and reperfusion of the ischemic myocardium can result in an elevated production of ROS (Jennings, Schaper et al. 1985). Thus, it is reasonable to speculate that brief hypertensive and hypotensive episodes, associated with enhanced BPV, also result in the increased production of ROS. Regarding the second question, there are several potential mechanisms and/or pathways that link oxidative stress with cardiovascular end-organ damage. While there is 87 a lack of data investigating the impact of oxidative stress specifically in models of increased BPV, it is generally thought that extraneous accumulation of ROS plays a crucial role in the genesis of cardiovascular pathology or in mediating secondary effects of established cardiovascular disease (Dhalla, Temsah et al. 2000). First, the results of this study demonstrate increased lipid peroxidation in the left and right cardiac ventricles after exposure to six weeks of enhanced BPV. Whereas the untreated SAD rats had signs of cardiac remodeling (hypertrophy and fibrosis), cardiac dysfunction (increased LV EDP), and increased cardiac tissue lipid peroxidation, all of these parameters were reduced by chronic tempol treatment. Additionally, it has been shown that BPV-induced lipid peroxidation in the aorta is associated with degeneration and apoptosis of the aortic endothelial cells along with decreased eNOS expression and endothelial-dependent dysfunction (Feng, Luo et al. 2011). Together, these findings would indicate that lipid peroxidation contributes significantly to BPV-induced cardiovascular end-organ damage. Lipid peroxidation is a hallmark of ROS-induced cellular injury (Dhalla, Temsah et al. 2000). As a result, cellular membrane lipid bilayer arrangement becomes disrupted which in turn can affect the functional properties of the cell (Grinna 1977). Furthermore, lipid peroxidation produces unsaturated aldehydes, such as MDA and other metabolites which are cytotoxic and mutagenic and capable of inactivating many cellular proteins by forming protein cross-linkages (Siu and Draper 1982; Hagihara, Nishigaki et al. 1984). In addition to the disruption of cell structure, ROS are known to regulate the activity of several enzymes essential for cellular growth or apoptosis (Dhalla, Golfman et al. 1999; Griendling, Sorescu et al. 2000). Several neurohormonal factors including catecholamines, AngII, and cytokines (TNF-α, TGF-β) are thought to convert cardiac 88 myocytes or fibroblasts into a pathologic phenotype by increasing intracellular oxidative stress, either via increased release of ROS or by decreasing antioxidant enzyme levels (Sorescu and Griendling 2002). For example, TGF-β is known to be released in response to Ang II and is thought to be a potent stimulant for the conversion of fibroblasts into active collagen producing myofibroblasts in a superoxide dependent pathway (Siwik, Pagano et al. 2001). In that study, treatment with the superoxide dismutase inhibitor diethyldithiocarbamic acid was able to decrease collagen synthesis. Upregulation of TGF-β and an increase in LV collagen deposition has been shown previously in mice following SAD (Martinka, Fielitz et al. 2005). Thus, tempol treatment may have prevented cardiac fibrosis in the experiments described in this thesis by preventing ROSinduced activation of TGF-β. Impaired endothelial-dependent dilation can be associated with decreased NO bioavailability and an increase in vasomotor tone. Decreased NO bioavailability may result from decreased NO synthesis or increased NO degradation through its interaction with ROS (Landmesser, Dikalov et al. 2003). Vasomotor tone can also be increased by the direct effects of ROS to increase intracellular calcium concentrations (Tabet, Savoia et al. 2004). The intracellular calcium-overload as a consequence of ROS may present another potential link between oxidative stress and cardiovascular end-organ damage as it can effect both pathologic cardiac remodeling (Dhalla, Temsah et al. 2000) and cardiac dysfunction (Dhalla, Golfman et al. 1999). Specifically, RAS-induced oxidative stress is thought to upregulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity, which may be a downstream sensor of both oxidative stress and intracellular calcium signals (Erickson, Joiner et al. 2008). CaMKII can activate the stress-activated and pro- 89 apoptotic p38MAPK (Takeda, Matsuzawa et al. 2004), which has been shown to be upregulated in mice after 12 weeks of SAD (Martinka, Fielitz et al. 2005). Furthermore, CaMKII is known to exert control over cardiac growth-related transcription factors in models of heart failure (Passier, Zeng et al. 2000). Because of the complexity of potential signal transduction pathways involved in cardiovascular remodeling it is likely that treatments focused on one specific area would not be as effective as a combination of therapies. This may explain why tempol treatment was only partially effective at preventing the structural and functional cardiovascular end-organ damage observed in the current study. See Figure 42 for a diagram summarizing the discussion of potential pathways linking elevated BPV with oxidative stress/ROS and subsequent cardiovascular damage. The specific cardiac and vascular changes observed in the experiments described in this thesis will be further discussed in the next two sections. Specific cardiac effects of enhanced BPV The results of this study suggest that six weeks of increased BPV result in a cardiac pathology that includes both structural remodeling and functional impairment. These changes are at least partially associated with an increase in oxidative stress. Cardiac weight was significantly increased by +14% compared to the Sham group whereas the normalized heart weight in the tempol-treated rats was not significantly greater (+7%) than the Sham group. Additionally, there was a trend (p= 0.2) for the untreated SAD group to have a greater percent area of connective tissue in the wall of the left ventricle compared to both the Sham and tempol-treated groups. This may suggest that BPV-induced increases in cardiac fibrosis take longer to develop compared to cardiac hypertrophy. The finding of an increase in cardiac weight is similar to previous 90 results that have observed an increase in the normalized weight of the LV of 11% after 6 weeks of SAD (Van Vliet, Hu et al. 1996). Similar increases in cardiac weight have also been observed after a period of 10 to 16 weeks (Miao and Su 2002; Xie, Miao et al. 2003; Zhang, Li et al. 2011) and have been associated with both increases in myocyte cross sectional area (Martinka, Fielitz et al. 2005; Takayama, Kai et al. 2011) and increased collagen deposition (Martinka, Fielitz et al. 2005; Tao, Zhang et al. 2008; Flues, MoraesSilva et al. 2012). The structural modifications of the heart observed following six weeks of SAD may be associated with a decrease in ventricular compliance. The loss of compliance or increase in ventricular stiffness manifests as elevated LV EDP. In contrast to the significant increase in LV EDP observed in this study, there was only a trend (p = 0.14) for LV contractility to be reduced. This may suggest that six weeks of SAD is not long enough to impair LV contractility. In studies that have investigated cardiac function after 10 (Flues, Moraes-Silva et al. 2012) or 12 weeks (Martinka, Fielitz et al. 2005) of SADinduced elevated BPV, evidence for both diastolic and systolic dysfunction were present. Together, these findings suggest the loss of diastolic function occurs prior to any changes in systolic function, which may only arise after seven to 10 weeks following SAD. Tempol treatment of SAD rats limited many of the pathologic cardiac changes observed in the untreated SAD group suggesting that oxidative stress may impact some cardiac parameters more than others. Interestingly, tempol treatment was able to prevent an increase in the amount of connective tissue observed in the wall of the left ventricle but only partially limited the increase in cardiac hypertrophy. Conflicting results have been described in the literature on the effects of tempol treatment on cardiac hypertrophy 91 and cardiac fibrosis (Zhang, Kimura et al. 2005; Moens, Takimoto et al. 2008; Rizzi, Castro et al. 2011). This discrepancy in the literature may be related to the research model used and other experimental conditions. Specific vascular effects of enhanced BPV Endothelial-dependent dilation of the LPCA in the denervated rats started to deviate from the response of the control group at week one and got progressively worse over the six week observation period. One of the major new findings in this study was the ability of tempol treatment to limit the loss of endothelial-dependent dilation compared to the untreated SAD group. During the initial week following the denervation surgery, there was a similar reduction in the ability of the LPCA to respond to vasodilating agents when comparing the untreated SAD rats and the tempol treated SAD rats. From week two through six, tempol treated SAD rats had a greater LPCA dilatory response to pilocarpine compared to untreated SAD rats. The endothelial-dependent dilation in the tempol treated group was only slightly decreased from that observed in the LPCA of the control group. Six weeks of SAD also resulted in endothelial-dependent vascular dysfunction in the middle cerebral artery (MCA) without reduced endothelial-independent dilation. Again, chronic tempol treatment was able to limit the endothelial-dependent vascular dysfunction in the MCA compared to the untreated SAD group. Interestingly, incubating the isolated MCA from chronically untreated rats (n = 2) in a tempol solution (10-3M) did not improve the blunted ACh dose response curve (data not shown). This finding suggests that chronically elevated BPV suppresses NO synthesis, which cannot be restored by acute ROS scavenging. Furthermore, the lack of an effect of acute tempol treatment, together with the beneficial effects of chronic tempol treatment to improve 92 endothelial-dependent dilation suggests that oxidative stress results in a more permanent, presumably structural modification of the endothelial cells thereby reducing the synthesis and release of NO. This may be related to ROS-induced endothelial progenitor cell degeneration and apoptosis (Bao, Wu et al. 2010). This is the first study showing a loss of endothelial-dependent function in small resistance type arteries (LPCA = 40 µm; MCA = 125 µm) following SAD. Previous studies have shown reduced endothelial-dependent dilation following SAD in large conduit-type arteries (Miao, Tao et al. 2001; Eto, Toba et al. 2003; Feng, Luo et al. 2011). Eto et al. (Eto, Toba et al. 2003) have suggested that the blunted ACh-dependent response they observed in the aorta following four weeks of SAD was due to a reduction in NO release and remodeling of the endothelial cell layer to enhance neointimal formation. Similarly, Feng et al. (Feng, Luo et al. 2011) have demonstrated reduced endothelial-dependent dilation of the aorta that was associated with increased apoptosis of endothelial cells and decreased eNOS expression in the aorta. Furthermore, their laboratory has provided evidence for an increase in the aortic tissue concentrations of both AngII and the lipid peroxidation byproduct MDA which would provide further support for the findings in this thesis and suggest an important role for local tissue RASinduced oxidative stress in the SAD model. While endothelial-dependent function was not investigated in the aorta in this study, there was a decrease in aortic distensibility that was observed immediately one week after SAD. Interestingly, inhibiting VSMC tone with an i.p. injection of the calcium channel blocker nifedipine improved aortic distensibility back to the level of the Shamoperated group. The improvement of aortic distensibility was only observed during the 93 first two weeks at which point the distensibility progressively decreased but still remained greater than when determined without inhibiting VSMC tone. This finding would suggest that the initial decrease in distensibility was due entirely to an increase in arterial tone. A combination of arterial tone and vascular remodeling may be responsible for the long-term loss of aortic distensibility. Furthermore, in the presence of nifedipine there was no difference in aortic distensibility between the untreated SAD rats and tempol-treated SAD rats. This suggests that the beneficial effects of tempol to improve aortic distensibility are related to reducing arterial tone. Thus, ROS may not be important for the structural component but only for the functional component related to the BPVinduced reduction in aortic distensibility. A previous study has shown a similar loss of aortic distensibility by investigating changes in the abdominal aorta after six weeks of SAD and attributed the changes to a structural modification of the arterial wall that included increases in collagen deposition and smooth muscle cell hypertrophy (Lacolley, Bezie et al. 1995). In the current study there was a significant increase in the aortic wall area suggesting the presence of structural vascular remodeling. There have been several previous studies that have shown similar structural modifications of the aorta to include medial smooth muscle cell growth and collagen accumulation in as little as two to four weeks following SAD (Miao, Tao et al. 2001; Miao and Su 2002; Shen, Zhang et al. 2006; Zhang, Li et al. 2011). Importance of assessing the time course of BPV-induced effects An important strength of this study is that the time course of hemodynamic parameters and functional and structural cardiac and vascular indices have been obtained 94 in a repeated measures design. For example, this approach revealed that SAD-induced BPV initially was 4-5 times higher than in the sham-operated group and gradually declined towards the end of the six-week observation period where it was still 2-3 times higher than in the control group. Interestingly, as BPV declined, BRS increased in a closely matching time course. The magnitude of BPV observed at the end of the study as well as the partial reduction of BPV over time is consistent with other reports (Miao and Su 2002; Flues, Moraes-Silva et al. 2012). In addition to the partial reduction in baroreflex buffering, the increase in BPV following SAD is also thought to result from the interaction of both neural and humoral factors acting on vascular smooth muscle to alter vascular tone (Alper, Jacob et al. 1987). Thus, the larger increase in BPV as well as the lower BRS that was observed during week one may reflect an initial over activation of the sympathetic nervous system. When measured in chronic SAD studies, sympathetic activation is generally thought to return to non-denervated levels after the first week (Irigoyen and Krieger 1998; Martinka, Fielitz et al. 2005). In contrast, there is an increase in the cardiac tissue content of AngII (Miao, Tao et al. 2001; Shan, Dai et al. 2003) and an increase in the circulating levels of vasopressin (Callahan, Ludwig et al. 1997). This suggests an equal or more prominent role for humoral factors such as the renin-angiotensin or vasopressin systems (Alper, Jacob et al. 1987) in the maintenance of significantly elevated BPV in chronic (> 1 week) SAD models. Alternatively, activation of humoral systems may be triggered as a compensatory mechanism meant to buffer the SAD-induced BPV. However, activation of these potential compensatory mechanisms – while initially improving blood pressure regulation to some extent – may also elicit deleterious effects on the cardiovascular 95 system as indicated by the loss of endothelial-dependent dilation and impaired cardiac function. Thus, loss of baroreceptor reflex function and increased BPV may trigger compensatory mechanisms, such as the tissue RAS, which subsequently initiate the chain of events leading to oxidative stress, lipid peroxidation, and ultimately cardiovascular end-organ damage. Study Considerations BP was not significantly different between the three groups during the six week observation period that started one week after SAD, confirming that the denervated rats were indeed normotensive. However, during the first week of observation BP and HR tended to be elevated in the two denervated groups compared to values in the Sham group. BP is known to be elevated immediately following the SAD procedure; however this acute hypertensive phase generally lasts less than seven days (Sved, Schreihofer et al. 1997). This initial hypertensive phase may have contributed to the observed changes in cardiovascular remodeling and function as we did not control for this in the current study. However, there has been some evidence to suggest the pathological changes observed with increased BPV still occur even after preventing the initial hypertensive episode with the ganglionic blocker hexamethonium bromide (Van Vliet, Hu et al. 1996; Van Vliet, Chafe et al. 1999). The significant reduction in the sensitivity of the baroreflex as well as the significantly increased variability within the systolic blood pressure suggests successful baroreceptor denervation in this study. It is important to note that the baroreceptor reflex was not completely abolished in the denervated rats as there was still a partial reflex HR response following changes in blood pressure. Alternatively, this could be viewed as a 96 strength of the study because a partial denervation would more closely mimic the common human condition of subtle baroreflex impairment (Ketch, Biaggioni et al. 2002) observed in elderly populations and those with chronic cardiovascular diseases such as hypertension or heart failure. The fact that aortic distensibility was the same in the tempol-treated and the untreated SAD rats following administration of nifedipine suggests that chronic tempol treatment can lower arterial tone. However, the precise mechanism relating tempol to the lower arterial tone cannot be determined from this study. It is known that vasomotor tone can be increased by the direct effects of ROS to increase intracellular calcium concentrations (Tabet, Savoia et al. 2004). There is also evidence that tempol may possess the ability to activate potassium channels or to act as a sympatholytic agent (Wilcox and Pearlman 2008). Both of these actions, in addition to antioxidant scavenging of ROS, may be involved in the reduction of arterial tone and other beneficial effects of tempol observed in this study. Summary and Conclusion The results of this study provide greater insight into some of the potential pathogenic mechanisms related to increased BPV-induced cardiovascular-end organ damage. Through the use of a novel in vivo imaging technique this is the first study to demonstrate a time course of endothelial-dependent dysfunction in resistance type arteries within the same animals. The important role of smaller arteries (20 - 150 µm) to regulate total peripheral resistance and the magnitude and distribution of tissue blood flow explains the need to further understand how these resistance-type vessels are impacted by pathologic stimuli such as increased BPV. The results of this study suggest 97 that chronically increased BPV results in a pro-oxidant environment in the heart and blood vessels that leads to cardiovascular damage. With this regard, this study shows that chronic treatment with the superoxide mimetic tempol is capable of limiting cardiovascular damage in the normotensive SAD model of increased BPV presumably by reducing oxidative stress. In conclusion, the cardiovascular pathology observed following SAD appears to be at least partly mediated by oxidative stress. Specific treatments (combination of scavenging and preventing ROS production) aimed at reducing the prooxidant environment in patients with increased BPV (e.g., hypertension, diabetes, heart failure) may prevent or ameliorate cardiovascular end-organ damage and reduce the overall risk of cardiovascular related morbidity and mortality. Perspective and Future Research Directions This study demonstrates the use of in vivo imaging of the LPCA to differentiate between endothelial-dependent and endothelial-independent vascular function by using corneal application of pilocarpine and SNP, respectively. It has been previously suggested that the LPCA could be considered as a model for the resistance arteries of the cerebral circulation because of its size and anatomical origin from the ophthalmic and internal carotid arteries (Stauss, Rarick et al. 2011). In the current study there was a significant correlation between the endothelial-dependent dilatory responses of the LPCA and the MCA. Thus, assessing structure and function of the LPCA by in vivo imaging may potentially be of considerable interest in research areas related to the cerebral circulation or stroke. Despite the fact that chronic tempol treatment has reduced or prevented cardiovascular end-organ damage in the current study as well as in other animal models 98 of increased oxidative stress (Elmedal, de Dam et al. 2004; Ritchie, Quinn et al. 2007; Rizzi, Castro et al. 2011; Fleenor, Seals et al. 2012), the use of chronic antioxidant treatments in large clinical trials has mostly failed to demonstrate significant beneficial effects on cardiovascular end points (Touyz 2004). This paradox may result from the variety of ROS that can be generated in different cellular locations by a multitude of enzymes (Dhalla, Temsah et al. 2000). Due to the different ROS characteristics it is possible that certain antioxidants may not be able to access the source of ROS production or may not have an equal scavenging effect on the different types of ROS produced (Touyz 2004). It may be a more efficacious treatment option to prevent ROS generation at the site of production as opposed to scavenging them after they have been produced. Preventing ROS production is thought to be one of the additional mechanisms by which some current cardiovascular drugs elicit their beneficial effects. For example, angiotensin receptor blockers are thought to decrease oxidative stress by directly inhibiting the ROS producing enzyme NADPH oxidase (Ghiadoni, Magagna et al. 2003). Future studies investigating the effect of increased BPV-induced oxidative stress on cardiovascular end-organ damage should determine both the source of oxidative stress (cellular location/generating enzymes) and the main stimulus that initiates ROS production (neural, humoral, stretch, intracellular calcium concentration). One important pathway to consider would be the renin-angiotensin system and the subsequent activation of CaMKII which is associated with increasing apoptosis and protein transcription. Angiotensin II is likely an important contributor to ROS production and may also lead to increased intracellular calcium concentration. It remains to be determined if the activity of CaMKII, which is a downstream sensor of both ROS and calcium signals, remains 99 upregulated by calcium when the pro-oxidant environment created by increased BPV is controlled by scavenging or preventing ROS production. 100 REFERENCES Alper, R. H., H. J. Jacob, et al. (1987). "Central and peripheral mechanisms of arterial pressure lability following baroreceptor denervation." Can J Physiol Pharmacol 65(8): 1615-1618. Alper, R. H., H. J. Jacob, et al. (1987). "Regulation of arterial pressure lability in rats with chronic sinoaortic deafferentation." Am J Physiol 253(2 Pt 2): H466-474. Andreyev, A. Y., Y. E. Kushnareva, et al. (2005). "Mitochondrial metabolism of reactive oxygen species." Biochemistry (Mosc) 70(2): 200-214. Baker, K. M., M. I. Chernin, et al. (1990). "Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats." Am J Physiol 259(2 Pt 2): H324332. Bao, X. M., C. F. Wu, et al. (2010). "Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK." Atherosclerosis 210(1): 114-121. Bendall, J. K., A. C. Cave, et al. (2002). "Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice." Circulation 105(3): 293-296. Blaschke, F., D. Bruemmer, et al. (2004). "C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells." Circulation 110(5): 579-587. Callahan, M. F., M. Ludwig, et al. (1997). "Baroreceptor input regulates osmotic control of central vasopressin secretion." Neuroendocrinology 65(4): 238-245. Castro, M. M., E. Rizzi, et al. (2009). "Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension." Free Radic Biol Med 46(9): 1298-1307. Chapleau, M. W. and F. M. Abboud (1994). "Modulation of baroreceptor activity by ionic and paracrine mechanisms: an overview." Braz J Med Biol Res 27(4): 10011015. Chapleau, M. W., J. T. Cunningham, et al. (1995). "Structural versus functional modulation of the arterial baroreflex." Hypertension 26(2): 341-347. Cheng, Y., X. B. Kong, et al. (1992). "Effects of ketanserin on blood pressure variability in conscious spontaneously hypertensive rats." Zhongguo Yao Li Xue Bao 13(3): 235-238. 101 Chess, D. J., W. Xu, et al. (2008). "The antioxidant tempol attenuates pressure overloadinduced cardiac hypertrophy and contractile dysfunction in mice fed a highfructose diet." Am J Physiol Heart Circ Physiol 295(6): H2223-2230. Chesterton, L. J., M. K. Sigrist, et al. (2005). "Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness." Nephrol Dial Transplant 20(6): 1140-1147. Danton, G. H. and W. D. Dietrich (2003). "Inflammatory mechanisms after ischemia and stroke." J Neuropathol Exp Neurol 62(2): 127-136. DeLano, F. A., G. W. Schmid-Schonbein, et al. (1991). "Penetration of the systemic blood pressure into the microvasculature of rat skeletal muscle." Microvasc Res 41(1): 92-110. Delbosc, S., J. P. Cristol, et al. (2002). "Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress." Hypertension 40(2): 142-147. DeMarco, V. G., J. Habibi, et al. (2008). "Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat." Am J Physiol Heart Circ Physiol 294(6): H2659-2668. Deng, L. Y., J. S. Li, et al. (1995). "Endothelium-dependent relaxation of small arteries from essential hypertensive patients: mechanisms and comparison with normotensive subjects and with responses of vessels from spontaneously hypertensive rats." Clin Sci (Lond) 88(6): 611-622. Dhalla, N. S., L. Golfman, et al. (1999). "Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review." Can J Cardiol 15(5): 587-593. Dhalla, N. S., R. M. Temsah, et al. (2000). "Role of oxidative stress in cardiovascular diseases." J Hypertens 18(6): 655-673. Dikalova, A., R. Clempus, et al. (2005). "Nox1 overexpression potentiates angiotensin IIinduced hypertension and vascular smooth muscle hypertrophy in transgenic mice." Circulation 112(17): 2668-2676. Durand, M. J., C. Moreno, et al. (2010). "Impaired relaxation of cerebral arteries in the absence of elevated salt intake in normotensive congenic rats carrying the Dahl salt-sensitive renin gene." Am J Physiol Heart Circ Physiol 299(6): H1865-1874. Eguchi, K., J. Ishikawa, et al. (2009). "Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes." Am J Hypertens 22(1): 46-51. 102 Elmedal, B., M. Y. de Dam, et al. (2004). "The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats." Br J Pharmacol 141(1): 105-113. Erickson, J. R., B. J. He, et al. (2011). "CaMKII in the cardiovascular system: sensing redox states." Physiol Rev 91(3): 889-915. Erickson, J. R., M. L. Joiner, et al. (2008). "A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation." Cell 133(3): 462-474. Eto, M., K. Toba, et al. (2003). "Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability." Hypertens Res 26(12): 991-998. Feng, J., H. Luo, et al. (2011). "Down-regulation of DDAH2 and eNOS induces endothelial dysfunction in sinoaortic-denervated rats." Eur J Pharmacol 661(1-3): 86-91. Figueroa, A., T. Baynard, et al. (2007). "Endurance training improves post-exercise cardiac autonomic modulation in obese women with and without type 2 diabetes." Eur J Appl Physiol 100(4): 437-444. Fleenor, B. S., D. R. Seals, et al. (2012). "Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice." Aging Cell 11(2): 269-276. Flues, K., I. C. Moraes-Silva, et al. (2012). "Cardiac and pulmonary arterial remodeling after sinoaortic denervation in normotensive rats." Auton Neurosci 166(1-2): 4753. Frattola, A., G. Parati, et al. (1993). "Prognostic value of 24-hour blood pressure variability." J Hypertens 11(10): 1133-1137. Ghiadoni, L., A. Magagna, et al. (2003). "Different effect of antihypertensive drugs on conduit artery endothelial function." Hypertension 41(6): 1281-1286. Goettsch, C., W. Goettsch, et al. (2009). "Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells." Biochem Biophys Res Commun 380(2): 355-360. Griendling, K. K., C. A. Minieri, et al. (1994). "Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells." Circ Res 74(6): 1141-1148. 103 Griendling, K. K., D. Sorescu, et al. (2000). "Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology." Arterioscler Thromb Vasc Biol 20(10): 2175-2183. Griendling, K. K., D. Sorescu, et al. (2000). "NAD(P)H oxidase: role in cardiovascular biology and disease." Circ Res 86(5): 494-501. Griendling, K. K. and M. Ushio-Fukai (2000). "Reactive oxygen species as mediators of angiotensin II signaling." Regul Pept 91(1-3): 21-27. Grinna, L. S. (1977). "Age related changes in the lipids of the microsomal and the mitochondrial membranes of rat liver and kidney." Mech Ageing Dev 6(3): 197205. Gurusamy, N., K. Watanabe, et al. (2006). "Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol." FEBS Lett 580(8): 1932-1940. Hagihara, M., I. Nishigaki, et al. (1984). "Age-dependent changes in lipid peroxide levels in the lipoprotein fractions of human serum." J Gerontol 39(3): 269-272. Hasegawa, H., H. Takano, et al. (2006). "Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects." Hypertens Res 29(9): 719-729. Irigoyen, M. C. and E. M. Krieger (1998). "Baroreflex control of sympathetic activity in experimental hypertension." Braz J Med Biol Res 31(9): 1213-1220. Jacob, H. J., C. P. Barres, et al. (1988). "Studies on neural and humoral contributions to arterial pressure lability." Am J Med Sci 295(4): 341-345. Jennings, R. B., J. Schaper, et al. (1985). "Effect of reperfusion late in the phase of reversible ischemic injury. Changes in cell volume, electrolytes, metabolites, and ultrastructure." Circ Res 56(2): 262-278. Johansson, M., S. A. Gao, et al. (2007). "Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure." J Hypertens 25(1): 163-168. Julien, C., Z. Q. Zhang, et al. (1993). "Role of vasoconstrictor tone in arterial pressure lability after chronic sympathectomy and sinoaortic denervation in rats." J Auton Nerv Syst 42(1): 1-10. Kai, H., H. Kudo, et al. (2009). "Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation." Circ J 73(12): 2198-2203. 104 Kaufmann, P. A. and P. G. Camici (2005). "Myocardial blood flow measurement by PET: technical aspects and clinical applications." J Nucl Med 46(1): 75-88. Ketch, T., I. Biaggioni, et al. (2002). "Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia." Circulation 105(21): 2518-2523. Krieger, E. M. (1964). "Neurogenic Hypertension in the Rat." Circ Res 15: 511-521. La Rovere, M. T., J. T. Bigger, Jr., et al. (1998). "Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators." Lancet 351(9101): 478-484. Lacolley, P., Y. Bezie, et al. (1995). "Aortic distensibility and structural changes in sinoaortic-denervated rats." Hypertension 26(2): 337-340. Landmesser, U., S. Dikalov, et al. (2003). "Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension." J Clin Invest 111(8): 1201-1209. Lassegue, B. and R. E. Clempus (2003). "Vascular NAD(P)H oxidases: specific features, expression, and regulation." Am J Physiol Regul Integr Comp Physiol 285(2): R277-297. Levy, B. I., E. L. Schiffrin, et al. (2008). "Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus." Circulation 118(9): 968-976. Liu, J. G., L. P. Xu, et al. (2003). "Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats." J Hypertens 21(10): 1961-1967. Mancia, G. (1983). "Methods for assessing blood pressure values in humans." Hypertension 5(5 Pt 2): III5-13. Mancia, G., A. Ferrari, et al. (1983). "Blood pressure and heart rate variabilities in normotensive and hypertensive human beings." Circ Res 53(1): 96-104. Mancia, G., A. Frattola, et al. (1994). "Blood pressure variability and organ damage." J Cardiovasc Pharmacol 24 Suppl A: S6-11. Mancia, G., G. Parati, et al. (1986). "Arterial baroreflexes and blood pressure and heart rate variabilities in humans." Hypertension 8(2): 147-153. 105 Martinka, P., J. Fielitz, et al. (2005). "Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex." Am J Physiol Regul Integr Comp Physiol 288(3): R767-776. Miao, C. Y. and D. F. Su (2002). "The importance of blood pressure variability in rat aortic and left ventricular hypertrophy produced by sinoaortic denervation." J Hypertens 20(9): 1865-1872. Miao, C. Y., X. Tao, et al. (2001). "Arterial remodeling in chronic sinoaortic-denervated rats." J Cardiovasc Pharmacol 37(1): 6-15. Miao, C. Y., H. H. Xie, et al. (2002). "Candesartan inhibits sinoaortic denervationinduced cardiovascular hypertrophy in rats." Acta Pharmacol Sin 23(8): 713-720. Modrick, M. L., S. P. Didion, et al. (2009). "Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging." Am J Physiol Heart Circ Physiol 296(6): H1914-1919. Moens, A. L., E. Takimoto, et al. (2008). "Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy." Circulation 117(20): 2626-2636. Molkentin, J. D. (2004). "Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs." Cardiovasc Res 63(3): 467-475. Monahan, K. D., F. A. Dinenno, et al. (2001). "Age-associated changes in cardiovagal baroreflex sensitivity are related to central arterial compliance." Am J Physiol Heart Circ Physiol 281(1): H284-289. Mulvany, M. J. (1996). "Effects of angiotensin converting enzyme inhibition on vascular remodelling of resistance vessels in hypertensive patients." J Hypertens Suppl 14(6): S21-24. Mulvany, M. J. (1999). "Vascular remodelling of resistance vessels: can we define this?" Cardiovasc Res 41(1): 9-13. Mulvany, M. J. (2012). "Small artery remodelling in hypertension." Basic Clin Pharmacol Toxicol 110(1): 49-55. Nakamura, K., K. Fushimi, et al. (1998). "Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II." Circulation 98(8): 794-799. 106 Nishiyama, A., T. Fukui, et al. (2001). "Systemic and Regional Hemodynamic Responses to Tempol in Angiotensin II-Infused Hypertensive Rats." Hypertension 37(1): 7783. Norman, R. A., Jr., T. G. Coleman, et al. (1981). "Continuous monitoring of arterial pressure indicates sinoaortic denervated rats are not hypertensive." Hypertension 3(1): 119-125. Pagano, P. J., S. J. Chanock, et al. (1998). "Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts." Hypertension 32(2): 331-337. Parati, G., G. Pomidossi, et al. (1987). "Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension." J Hypertens 5(1): 93-98. Passier, R., H. Zeng, et al. (2000). "CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo." J Clin Invest 105(10): 13951406. Patakas, D., G. Louridas, et al. (1982). "Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease." Thorax 37(4): 292-295. Piccirillo, G., C. Bucca, et al. (1996). "Heart rate and blood pressure variabilities in saltsensitive hypertension." Hypertension 28(6): 944-952. Piccirillo, G., M. Nocco, et al. (2003). "Influence of vitamin C on baroreflex sensitivity in chronic heart failure." Hypertension 41(6): 1240-1245. Pimentel, D. R., J. K. Amin, et al. (2001). "Reactive oxygen species mediate amplitudedependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes." Circ Res 89(5): 453-460. Qamirani, E., Y. Ren, et al. (2005). "C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase." Arterioscler Thromb Vasc Biol 25(5): 995-1001. Rajagopalan, S., S. Kurz, et al. (1996). "Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone." J Clin Invest 97(8): 1916-1923. Ritchie, R. H., J. M. Quinn, et al. (2007). "The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo." J Mol Cell Cardiol 42(6): 1119-1128. 107 Rizzi, E., M. M. Castro, et al. (2011). "Tempol inhibits TGF-beta and MMPs upregulation and prevents cardiac hypertensive changes." Int J Cardiol. Robinson, T. G. and S. J. Carr (2002). "Cardiovascular autonomic dysfunction in uremia." Kidney Int 62(6): 1921-1932. Rostagno, C., M. Felici, et al. (1999). "Decreased baroreflex sensitivity assessed from phase IV of Valsalva maneuver in mild congestive heart failure." Angiology 50(8): 655-664. Rugale, C., S. Delbosc, et al. (2007). "Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine." J Cardiovasc Pharmacol 50(3): 293-298. Schnackenberg, C. G., W. J. Welch, et al. (1998). "Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide." Hypertension 32(1): 59-64. Schunkert, H., V. J. Dzau, et al. (1990). "Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation." J Clin Invest 86(6): 1913-1920. Shan, Z. Z., S. M. Dai, et al. (2003). "[Angiotensin II contents in plasma, and cardiac and renal tissues of sinoaortic denervated rats]." Sheng Li Xue Bao 55(1): 75-78. Shan, Z. Z., S. M. Dai, et al. (2001). "Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats." J Cardiovasc Pharmacol 38(3): 427-437. Shen, F. M., S. H. Zhang, et al. (2006). "Early structural changes of aortic wall in sinoaortic-denervated rats." Clin Exp Pharmacol Physiol 33(4): 358-363. Simonsen, U., F. H. Christensen, et al. (2009). "The effect of tempol on endotheliumdependent vasodilatation and blood pressure." Pharmacol Ther 122(2): 109-124. Simonsen, U., R. Rodriguez-Rodriguez, et al. (2009). "Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation." Pharmacol Rep 61(1): 105-115. Siu, G. M. and H. H. Draper (1982). "Metabolism of malonaldehyde in vivo and in vitro." Lipids 17(5): 349-355. Siwik, D. A., P. J. Pagano, et al. (2001). "Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts." Am J Physiol Cell Physiol 280(1): C53-60. 108 Sorescu, D. and K. K. Griendling (2002). "Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure." Congest Heart Fail 8(3): 132-140. Stauss, H. M. and P. B. Persson (2000). "Role of Nitric Oxide in Buffering Short-Term Blood Pressure Fluctuations." News Physiol Sci 15: 229-233. Stauss, H. M., K. R. Rarick, et al. (2011). "Noninvasive assessment of vascular structure and function in conscious rats based on in vivo imaging of the albino iris." Am J Physiol Regul Integr Comp Physiol 300(6): R1333-1343. Stefanadis, C., J. Dernellis, et al. (2000). "Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease." Eur Heart J 21(5): 390-396. Sved, A. F., A. M. Schreihofer, et al. (1997). "Blood pressure regulation in baroreceptordenervated rats." Clin Exp Pharmacol Physiol 24(1): 77-82. Tabet, F., C. Savoia, et al. (2004). "Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats." J Cardiovasc Pharmacol 44(2): 200-208. Takayama, N., H. Kai, et al. (2011). "Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways." Hypertens Res 34(3): 341-347. Takeda, K., A. Matsuzawa, et al. (2004). "Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation." EMBO Rep 5(2): 161-166. Tao, X., Y. J. Zhang, et al. (2008). "Fosinopril prevents the pulmonary arterial remodeling in sinoaortic-denervated rats by regulating phosphodiesterase." J Cardiovasc Pharmacol 51(1): 24-31. Tokuda, K., H. Kai, et al. (2004). "Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis." Hypertension 43(2): 499-503. Touyz, R. M. (2004). "Reactive oxygen species and angiotensin II signaling in vascular cells -- implications in cardiovascular disease." Braz J Med Biol Res 37(8): 12631273. Touyz, R. M. (2004). "Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?" Hypertension 44(3): 248-252. 109 Touyz, R. M., F. Tabet, et al. (2003). "Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension." Clin Exp Pharmacol Physiol 30(11): 860866. Trapani, A. J., K. W. Barron, et al. (1986). "Analysis of hemodynamic variability after sinoaortic denervation in the conscious rat." Am J Physiol 251(6 Pt 2): R11631169. Trott, D. W., J. W. Seawright, et al. (2011). "NAD(P)H oxidase-derived reactive oxygen species contribute to age-related impairments of endothelium-dependent dilation in rat soleus feed arteries." J Appl Physiol 110(5): 1171-1180. Van Vliet, B. N., L. L. Chafe, et al. (1999). "Contribution of baroreceptors and chemoreceptors to ventricular hypertrophy produced by sino-aortic denervation in rats." J Physiol 516 ( Pt 3): 885-895. Van Vliet, B. N., L. Hu, et al. (1996). "Cardiac hypertrophy and telemetered blood pressure 6 wk after baroreceptor denervation in normotensive rats." Am J Physiol 271(6 Pt 2): R1759-1769. Wang, Y. (2007). "Mitogen-activated protein kinases in heart development and diseases." Circulation 116(12): 1413-1423. Wei, Y., A. T. Whaley-Connell, et al. (2007). "NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat." Hypertension 50(2): 384-391. Wilcox, C. S. and A. Pearlman (2008). "Chemistry and antihypertensive effects of tempol and other nitroxides." Pharmacol Rev 60(4): 418-469. Xie, H. H., C. Y. Miao, et al. (2003). "Effects of long-term treatment with candesartan on organ damages in sinoaortic denervated rats." J Cardiovasc Pharmacol 41(2): 325331. Yagi, S., M. Akaike, et al. (2010). "Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury." Hypertension 55(4): 918-923. Yang, Z. W., D. J. Li, et al. (2011). "Role of vascular K(ATP) channels in blood pressure variability after sinoaortic denervation in rats." Acta Pharmacol Sin 32(2): 194200. Zhang, G. X., S. Kimura, et al. (2005). "Cardiac oxidative stress in acute and chronic isoproterenol-infused rats." Cardiovasc Res 65(1): 230-238. 110 Zhang, L. C., Z. Z. Li, et al. (2011). "Angiotensin-converting enzyme and Angiotensinconverting enzyme 2 are involved in sinoaortic denervation-induced cardiovascular hypertrophy in rats." Biol Pharm Bull 34(9): 1398-1403. Zicha, J., Z. Dobesova, et al. (2001). "Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: the possible role of superoxide anions." J Hypertens 19(2): 247-254.